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SUMMARY 
Proteins are a very diverse family of large organic compounds involved in many important 
biological processes. Following their enzymatic hydrolysis during food processing or 
digestion, proteins may release fragments from their primary amino acid sequence. These 
fragments are called peptides, and many of them are known to be physiologically active. The 
possible beneficial effects of bioactive peptides have attracted increasing interest in recent 
years. On the other hand, there are also reports suggesting that some food-derived peptides 
might adversely affect human health. Among these, β-casomorphin-7 (BCM7), a peptide 
sequence present in the milk protein β-casein, has been suggested to contribute to an 
increased risk for certain non-communicable diseases, such as autism, cardiovascular diseases 
and type I diabetes. Some literature reports have proposed possible mechanistic explanations 
for such associations   
Recognising the alleged negative effect of BCM7 on human health, EFSA deemed it 
necessary to perform a comprehensive review of the published scientific literature in order to 
assess the relationship of this peptide and related peptides with non-communicable diseases.  
The review covers the following aspects: possible sources of β-casomorphins (BCMs) and 
related peptides, polymorphism of β-casein, presence of BCMs and related peptides in food 
before digestion, formation of BCM7 and related peptides during human digestion and the 
possible molecular interactions of these peptides with the host environment. Furthermore, it 
covers the absorption and fate of these peptides, including their possible transfer mechanisms 
across the intestinal epithelium, transport in the blood stream and transfer across the blood-
brain barrier. Finally, possible and suggested organ- and system-specific effects are reviewed, 
with specific emphasis on the gastrointestinal, central nervous and cardiovascular systems and 
the suggested link with type 1 diabetes mellitus. 
This review recognises that proteins, including those present in the diet, are a potential source 
of a wide range of biologically active peptides, including some with affinity to opioid 
receptors. The latter are also known as opioid peptides. Opioid peptide sequences have been 
characterised in animal and plant proteins. To date much work has focused on characterising 
opioid peptides derived from milk proteins, in particular the caseins. Beta-casomorphins are a 
group of opioid peptides which can be released from β-casein. The β-casein derived peptide 
with the sequence Tyr60-Pro61-Phe62-Pro63-Gly64-Pro65-Ile66 is known as β-casomorphin-7. 
The release of BCM7 through enzymatic digestion of bovine β-casein is dictated by different 
amino acid sequences of this protein. The sequences vary genetically between cow breeds. 
The amino acid present in position 67 of the sequence in β-casein appears to be critical for the 
release of BCM7. In the A2 variant of β-casein a Proline residue occurs at position 67, 
whereas the A1 and B variants of β-casein have a Histidine residue at this position. In the case 
of the variants containing Proline the enzymatic hydrolysis of the Ile66-Pro67 bond does not 
occur or occurs at a very low rate.  
The proportion of the different protein variants expressed in the milk, including those of β-
casein, is related to their allele distributions in the various cattle breeds and populations. 
Changing selection targets in the last decades has resulted in changes in bovine breed 
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composition in most European countries. While no detailed information is available, it is 
likely that these changes in breed composition have had an impact on milk composition, 
including protein variants. Taking into account the lack of detailed knowledge in milk protein 
variant composition and the diverse geographical origin of dairy products and ingredients 
across Europe, insufficient information is currently available on the exposure of individual 
consumers to different β-casein variants. 
It would appear that fresh raw/unprocessed milk obtained from healthy cows does not contain 
BCM7 or related peptides. By contrast, there is a substantial body of evidence indicating that 
different proteolytic systems involved in fermented milk or cheese manufacture can 
potentially hydrolyze β-casein to BCM7 or other BCMs and further degrade these peptides to 
shorter-chain peptides and even amino acids. However, little or no information is currently 
available about the actual BCM levels which different proteolytic systems may generate in 
fermented or enzyme-treated milk products. Furthermore, the stability of these peptides in the 
food products, once generated, is variable. Technological conditions, such as heat treatments, 
applied in industrial dairy processing do not seem to influence the occurrence of BCMs in 
final products or influence their formation during subsequent digestion. Moreover, limited 
information is available on the occurrence of BCMs in commercial infant formulas. 
The role of proteolytic systems in the release of BCMs during simulated gastrointestinal 
digestion (SGID) or in vivo digestion, has not been fully clarified. No current studies report 
quantitative values for the formation of BCMs during in vivo digestion of dairy products. 
However, there are indications that the sequential action of several digestive enzymes may be 
involved and the formation of certain BCMs after SGID (with multiple enzyme activities) has 
been demonstrated. 
Animal data clearly indicate that BCMs, including BCM7, can act as opioid receptor agonists, 
probably acting via μ-type opioid receptors. However, in most if not all animal studies to date, 
in vivo opioid effects for BCM7 and related milk-derived peptides have only been observed 
following intra-peritoneal (i.p.) or intra-cerebro-ventricular (i.c.v.) administration. In 
comparison to medicinal and endogenous opioids, bovine BCM7 does not seem to be a very 
potent opioid ligand. 
A prerequisite for opioid activity after oral ingestion is that the peptides must pass the 
intestinal epithelial barrier. In addition, subsequent biotransformation in the liver and stability 
in plasma may be factors determining the ultimate biological activity. Finally, passage 
through the blood-brain-barrier is in principle needed for an activity in the central nervous 
system. Relatively little is known on the mechanisms of transfer of intact peptides longer than 
3 amino acids across the intestinal barrier. If this transport occurs, then the extent is very low 
and passive diffusion is the most likely transfer mechanism. The presence of β-casomorphin 
immunoreactive material has been reported in blood in two studies with neonatal dogs and 
calves. However, the presence of intact β-casomorphin molecules in blood after intake of milk 
or casein has not been established in in vivo studies. Opioid peptides, including β-
casomorphin 4, -5 and -7 are highly sensitive to hydrolysis by dipeptidyl peptidase IV thereby 
strongly limiting or preventing the transfer of these peptides in an intact form across the 
intestinal mucosa and the blood-brain barrier. Available data suggest that in principle, 
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transport of food-derived peptides and proteins across the human intestinal mucosa is 
possible. However, quantitative data on this phenomenon are lacking. In certain cases such as 
in neonates and adults with specific diseases, intestinal permeability has been reported to be 
significantly increased. In general, the review did not find any quantitative data on the 
absorption of intact bioactive peptides for adults, except in the case for di- and tripeptides 
with reported antihypertensive properties. 
Food-derived peptides, including casomorphins, can have different effects in the intestinal 
lumen and the intestinal mucosa, such as regulatory effects on gastro-intestinal motility and 
on gastric and pancreatic secretions. Many studies report effects of β-casomorphins on the 
central nervous system (CNS) following i.p. or i.c.v. administration in animals. A possible 
link between BCM intake and sudden infant death syndrome (SIDS) has been suggested in 
some publications. However, no clear evidence for such a relationship was found during the 
review. The mechanisms proposed were considered rather speculative and partly 
contradictory. Similarly, a link between casein-derived peptides and autism in subjects with 
increased intestinal permeability has been suggested. However, recent data do not provide any 
support for such a relationship. 
It has been suggested that BCM7 might be atherogenic through an oxidative action on LDL. 
This mechanism was originally proposed in a single report; however, it has not been 
confirmed by later studies. By contrast, numerous in vitro studies indicate that many food 
derived peptides/hydrolysates display antioxidant activity. The possibility that BCM7 could 
contribute to an increased risk for atherosclerosis has also been suggested from a study in a 
rabbit model. This study concluded that β-casein A1 would be atherogenic, in contrast to β-
casein A2. However, during the review the validity of the experimental model and the 
extrapolation to atherosclerosis in humans were not regarded as convincing. Further 
speculations for an association between BCM7 intake and cardiovascular disease mortality 
have been raised as a result of ecological studies. However, these ecological studies did not 
account for several confounding factors. In addition, recent large cohort studies led to 
opposite conclusions. Two human intervention studies comparing diets containing β-casein 
A1 and A2 did not show a correlation between the estimated β-casein A1 consumption and 
development of certain biomarkers for cardiovascular disease (CVD). A limitation of these 
studies was the small number of subjects and the short intervention period. Overall, this 
review process did not find any strong evidence for a link between the consumption of β-
casein A1 and an increased risk for CVD in humans. 
Insulin dependent diabetes mellitus (IDDM) is recognised as a multifactorial autoimmune 
disease; however, its pathogenesis is unclear. Autoantibodies have been found in IDDM 
patients, but the role of autoantibodies in type 1 diabetes is currently not known. These 
autoantibodies have not been proven to be directly involved in either tissue destruction or 
disease progression. The development of IDDM is the result of a combination of genetic 
predisposition and environmental risk factors where genetic predisposition is a necessary 
condition. 
Many dietary risk factors of IDDM have been indicated, including short duration of breast 
feeding, as well as administration of gluten, soy, cow’s milk and solid foods at young age. 
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Several different milk proteins or peptides derived from these proteins have been proposed as 
possible diabetogenic factors. The mechanism most often suggested is immunological. The 
diabetogenicity of β-casein A1, A2 and B has been evaluated in animal studies and ecological 
studies on humans. Animal studies have presented contradictory results. 
Some ecological studies have linked the intake of BCM7 with IDDM. Ecological studies have 
the shortcoming of being unable to establish a cause-effect association and they cannot adjust 
for possible confounding factors. They are at best indicating a hypothesis but cannot provide a 
proper base to demonstrate a cause-effect relationship. 
The correlations suggested by such studies may become very weak when taking into account 
the uncertainties in individual consumption, in the β-casein variant composition, and in some 
countries also the IDDM incidence rate. 
Moreover, the difference in content of β-casein A1+B in milk produced in countries with high 
or low prevalence of IDDM appears relatively small and does not explain, from an  
immunological point of view, the difference in incidence of IDDM across countries. 
Based on the present review of available scientific literature, a cause-effect relationship 
between the oral intake of BCM7 or related peptides and aetiology or course of any suggested 
non-communicable diseases cannot be established. Consequently, a formal EFSA risk 
assessment of food-derived peptides is not recommended. 
 
Key Words: food-derived peptides, opioid peptides, β-casein, β-casomorphin, β-
casomorphin-7, IDDM, CVD, SIDS, autism 
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BACKGROUND 
Proteins are a broad family of large organic compounds playing a central role in the structure 
and functionality of all living organisms. Besides their structural and functional roles proteins 
are also a fundamental component of animal and human diets providing a source of energy, 
nitrogen and essential amino acids. In addition, dietary proteins may also provide a source of 
biologically active peptides. Such peptides are inactive within the sequence of the precursor 
protein but may be released from their respective animal, plant or microbial proteins by 
hydrolysis during food processing or digestion. Food-derived bioactive peptides may 
influence regulatory functions in the human system beyond normal nutrition. A range of food 
protein derived peptides have been found to be potentially physiologically active, i.e., 
bioactive. These bioactivities include modulation of gut secretion and motility, blood 
pressure-lowering, antithrombotic, antioxidant, antimicrobial and immunomodulatory 
activities. Some of these effects are mediated by interaction with the opioid system (Mine and 
Shahidi, 2006). 
On the one hand the discovery of bioactive peptides with potential health benefits has been 
the subject of growing commercial interest in the context of health-promoting functional 
foods. To date milk proteins have been most extensively studied as a source of these peptides. 
The opioid receptor system is of particular interest since it has been proposed as one of 
several possible links between physiological effects and the intake of food protein derived 
peptides. Food derived peptides which bind to opioid receptors are known as exogenous 
opioid peptides. Some evidence exists, for example, to indicate that these peptides may 
beneficially modulate several gastrointestinal functions (Teschemacher, 2003). Milk proteins, 
including both caseins and whey proteins are a source of many peptides with opioid activities, 
including casomorphins and lactorphins. The in vivo physiological effects of many of these 
peptides, however, remain to be fully elucidated. 
On the other hand, there are reports of potential adverse health effects of food-derived opioid 
peptides. Some ecological studies have suggested that the milk derived peptide BCM7 
(BCM7) or related compounds may be involved in the development of a diverse range of 
serious human diseases, such as juvenile diabetes type I, ischemic heart disease, autism and 
schizophrenia (Elliott et al., 1999; McLachlan, 2001). A number of different biological 
mechanisms have been suggested for the adverse effects of BCM7 and related compounds, 
based on their opioid, lipid oxidation (Torreilles et al., 1995), histamine release (Kurek et al., 
1992) and immunological activities (Padberg, 1999; Pozzilli, 1999). The possible release of 
BCM7 during protein digestion is generally reported to be dependent on the presence of 
specific genetic variants of β-casein, specifically variants A1 and B of bovine β-casein 
(Hartwig, 1997; Jimsmaa et al., 1999).   
TERMS OF REFERENCE 
To collect and review the available scientific evidence related to BCM7 and analogous 
peptides with similar characteristics, with the purpose to assess the existence and robustness 
of an association between such bioactive peptides originating from food and non-
communicable diseases. The detailed objectives include: 
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• Possible occurrence of BCM7 or related peptides as a function of genetic variability of the 
food source; 
• Factors leading to their formation, absorption in the intestinal tract and metabolic 
pathways;  
• Identification of possible specific vulnerability of particular sub-populations; 
• Mechanisms of action of these peptides in the body, including immunological effects; 
• A critical assessment  of epidemiological evidence of adverse health effects in humans; 
• A critical evaluation of experimental evidence in animals fed with diets leading to high 
levels of BCM7 or analogous peptides. 
Following this review and depending on its outcome EFSA will decide whether there are 
sufficient indications to justify a full risk assessment of the consumption of food that can 
potentially produce such bioactive peptides during digestion. Should the review identify a 
lack of information on which to base a reasonable decision the need for any further research 
will be highlighted. 
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ASSESSMENT 
Different approaches are possible to assess the robustness of an alleged association between 
consumption of a substance and non-communicable diseases. Nevertheless, some common 
criteria may be identified to test a cause-effect hypothesis (WHO, 2008; US-FJC, 2000). 
These include 
• temporal relationship; 
• strength of the association; 
• dose–response relationship; 
• substantial convergence of the studies (replication of the findings); 
• biological plausibility (including mechanisms of transport and mechanisms of action); 
• consideration of alternative explanations; 
• effects on cessation of exposure; 
• specificity of response 
• consistency with other knowledge. 
 
The present review takes into account these suggestions, focusing on different relevant 
aspects: 
• Possible sources of β-casomorphins and related peptides 
• Polymorphism of β-casein 
• Presence of β-casomorphins and related peptides in food before digestion 
• Formation of β-casomorphins and related peptides during human digestion 
• Possible molecular interactions of these peptides 
• Absorption and fate of these peptides, including transfer mechanisms across the intestinal 
epithelium, transport in the blood stream and transfer across the blood-brain barrier 
• Organ and system-specific suggested action of food-derived peptides, focusing on the 
gastrointestinal system, the central nervous system, the cardiovascular system and type 1 
diabetes mellitus 
1 INTRODUCTION 
Proteins are a very broad family of large organic compounds playing a central functional and 
structural role in living organisms. Chemically proteins are linear polymers built from 
different L-α-amino acids. All 20 amino acids possess common structural features, including a 
α carbon to which an amino group, a carboxyl group, and a variable side chain are bonded. 
Only proline differs from this basic structure as it contains an unusual ring to the N-end amine 
group, which forces the CO–NH amide moiety into a fixed conformation. The side chains of 
the standard amino acids have different chemical properties that produce a three-dimensional 
protein structure and different activities. The amino acid sequence is therefore of critical 
importance for the protein functionality/biofunctionality. 
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The amino acids in a polypeptide chain are linked by peptide bonds. Once linked in the 
protein chain, an individual amino acid is called a residue, and the linked series of carbon, 
nitrogen, and oxygen atoms are known as the main chain or protein backbone. The peptide 
bond has two resonance forms that contribute some double-bond character and inhibit rotation 
around its axis, so that the α-carbons are roughly coplanar. The other two dihedral angles in 
the peptide bond determine the local shape assumed by the protein backbone. 
Due to the chemical structure of the individual amino acids, the protein chain has 
directionality. The end of the protein with a free carboxyl group is known as the C-terminus 
or carboxy terminus, whereas the end with a free amino group is known as the N-terminus or 
amino terminus. Amino acids in a polypeptide chain are numbered starting from the N-
terminus. 
The sequence of amino acids in a protein is crucial to the role it plays in a living organism, 
and each protein is defined by a gene and encoded in the genetic code.  
Different terms are used to define linear sequences of amino acids, such as protein, 
polypeptide, and peptide. The meaning of these terms can sometimes overlap, however, 
protein is generally used to refer to the complete biological molecule in a stable conformation, 
whereas peptide is generally reserved for short amino acid oligomers. The boundary between 
the two terms is not well defined and is usually considered at about 20–30 residues. 
Polypeptide is a general term for any single linear chain of amino acids, usually regardless of 
length. 
Besides their roles in the structure and functionality of the organism, proteins are also a 
fundamental component of animal and human diet providing a source of energy, nitrogen and 
essential amino acids. To this purpose dietary proteins need to undergo a breakdown process 
known as digestion, which is carried out by many different hydrolytic enzymes that 
progressively lead to the formation of peptides and free amino acids. Enzymes are site-
specific in their cleavage action on the polypeptide chain, some being more selective than 
others. Depending on the enzymes involved, digestion of a single dietary protein may involve 
formation of different patterns of intermediate peptides. 
2 BIOACTIVE PEPTIDES AND SOURCE PROTEINS 
2.1 Protein precursors for bioactive peptides 
Globally, public health professionals in particular, but also consumers, food producers and 
food processors, are becoming increasingly aware of the rapidly expanding body of 
epidemiological evidence linking the prevalence of diseases, such as cardiovascular disease, 
obesity, hypertension, diabetes and even cancer to dietary factors. This has led to an increased 
interest in the potential health effects of food derived bioactive components. Food proteins 
contain various peptide sequences encrypted within their primary structures which possess 
potential biological activity. These proteins originate from a range of different sources 
including animals, fish, plants and bacteria (Mine and Shahidi, 2006). These bioactive 
peptides may be released from their parent protein molecule either during food processing 
and/or during gastrointestinal digestion. 
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Depending on their site of action, these peptide sequences may or may not be required to be 
transported across the intestinal mucosa in order to mediate a physiological response. Such 
bioactive peptides range in size from 2 to 50 amino acid residues and may have numerous 
physiological functions within the body. Peptides, for example, having hypotensive, 
immunomodulatory, antibacterial, mineral binding, antithrombotic along with opioid agonist 
and antagonist activities have been reported. The literature on milk protein derived bioactive 
peptides has been extensively reviewed (Clare and Swaisgood, 2000; FitzGerald and Meisel, 
2003; Korhonen and Pihlanto, 2003; Pihlanto and Korhonen, 2003; Meisel, 2004; Walsh and 
FitzGerald, 2004; Korhonen and Pihlanto, 2006; Gobbetti et al., 2007; Hartmann and Meisel, 
2007; Korhonen and Pihlanto, 2007; Murray and FitzGerald, 2007; Morris and FitzGerald, 
2008). The literature indicates that these peptides potentially impact the cardiovascular, 
nervous, digestive and immune systems (Figure 1). 
 
Figure 1: Potential physiological functionality of food-derived bioactive peptides (adapted from 
Korhonen and Pihlanto, 2007) 
In order to become active in the body it is considered very critical that a bioactive peptide first 
reaches its molecular target. This subject will be further discussed in chapter 4.4.  
2.2 Food protein sources of opioid peptides 
Many different food protein molecules contain peptide sequences which behave as opioid 
receptor ligands (Henschen et al., 1979, Zioudrou et al., 1979, Brantl et al., 1986a, Paroli 
1988, Teschemacher 2003, Kostyra et al., 2004, Guesdon et al., 2006). It has been reported 
that opioid peptides can be formed from milk, cereal, vegetable and meat/poultry proteins 
(Table 1). Furthermore, various blood proteins, including albumin and γ-globulins (Zioudrou 
et al., 1979) and haemoglobin (Brantl et al., 1986b) may act as a source of opioid peptides. In 
addition, the egg protein, ovalbumin also appears to contain opioid peptide sequences 
(Zioudrou et al., 1979). 
CARDIOVASCULAR 
SYSTEM 
NERVOUS SYSTEM
DIGESTIVE SYSTEM
IMMUNE SYSTEM
Antioxidative
Hypocholesterolemic
Opioid
Antithrombotic
Antagonist activity
Mineral-binding
Immunomodulatory
Antimicrobial
Antihypertensive
Agonist activity
Cytomodulatory
Anti-appetizing
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Table 1: Food protein sources of opioid receptor ligands/peptides (adapted from 
Teschemacher, 2003) 
Food Group Foodstuff Protein precursor Reference 
Dairy Milk and milk products α-Casein (Zioudrou et al., 1979) 
  β-Casein (Brantl et al., 1979) 
  κ-Casein (Chiba et al., 1989) 
  α-Lactalbumin (Yoshikawa et al., 1986) 
  β –Lactoglobulin (Yoshikawa et al., 1986) 
  Lactoferrin (Tani et al., 1990) 
Cereals Wheat Gluten (Fukudome and Yoshikawa, 
1992) 
  Gliadin (Zioudrou et al., 1979) 
 Barley Hordein (Zioudrou et al., 1979) 
  Avenin (Zioudrou et al., 1979) 
  Secalin (Zioudrou et al., 1979) 
  Zein (Zioudrou et al., 1979) 
 Rice Albumin (Takahashi et al., 1994) 
Vegetable Soy α-Protein (Zioudrou et al., 1979) 
 Spinach Rubisco (Yang et al., 2003) 
Meat/poultry Blood Albumin (Zioudrou et al., 1979) 
  Haemoglobin (Brantl et al., 1986b ) 
  γ-Globulin (Zioudrou et al., 1979) 
 Egg Ovalbumin (Zioudrou et al., 1979) 
 
Food protein derived opioid peptides are classified as exogenous opioids in that while they 
possess a Tyr residue within their sequence, usually at the N-terminus or in the N-terminal 
region, they differ from the endogenous opioid peptides which often have Tyr-Gly-Gly-Phe as 
the N-terminal sequence (Teschemacher, 2003). In most cases these exogenous peptides have 
been isolated and subsequently identified from enzymatic digests of their parent protein 
molecules. However, in some cases, synthetic peptides corresponding to specific regions 
within intact food protein molecules have been shown to act as opioid receptor ligands.  
Milk proteins are the most studied with respect to the presence of opioid peptide sequences 
and have been extensively reviewed in the literature (Meisel, 1997; Teschemacher et al., 
1997; Meisel and FitzGerald, 2000; Pihlanto-Leppälä, 2000; Guesdon et al., 2006). Most 
studies have been performed with bovine milk proteins, but there are a limited number of 
studies on opioid peptides from water buffalo (Petrilli et al., 1984) and from human milk 
(Brantl, 1984; Koch et al., 1985; Ferranti et al., 2004).  
As can be seen from Table 1, all the major milk proteins contain opioid receptor ligands. 
These have been specifically termed exorphins and casoxin D when derived from α-casein, β-
casomorphins and β-casorphins when derived from β-casein, casoxins (A, B, C) when derived 
from κ-casein, α-lactorphins when derived from α-lactalbumin, β-lactorphins when derived 
from β-lactoglobulin and lactoferroxins when derived from lactoferrin. The majority of the 
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milk peptides identified to date behave as opioid agonists while the casoxins and 
lactoferroxins behave as opioid antagonists. 
Table 2 provides specific details of opioid peptide sequences from different food protein 
sources. 
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Table 2: Parent protein precursors and associated opioid peptide sequences from different 
food protein sources. 
Origin Structure 
Bovine Milk  
α-lactorphin, α -la f(50-53) Tyr-Gly-Leu-Phe (YGLF) 
β-lactorphin, β-lg f(102-105) Tyr-Leu-Leu-Phe (YLLF) 
αS1-casein-exorphin, αs1-cn f(90-96) Arg-Tyr-Leu-Gly-Tyr-Leu-Glu (RYLGYLE) 
β-casomorphin 4,  β-cn f(60-63)   Tyr-Pro-Phe-Pro (YPFP) 
β-casomorphin 5,  β-cn f(60-64) Tyr-Pro-Phe-Pro-Gly (YPFPG) 
β-casomorphin 7, β-cn f(60-66) Tyr-Pro-Phe-Pro-Gly-Pro-Ile (YPFPGPI) 
β-casomorphin 8, β-cn f(60-67) Tyr-Pro-Phe-Pro-Gly-Pro-Ile-Pro/His (YPFPGPIP/H) 
Casoxin A, κ-cn f(35-42) Tyr-Pro-Ser-Tyr-Gly-Leu-Asn-Tyr (YPSYGLNY) 
Casoxin B, κ-cn f(58-61) Tyr-Pro-Tyr-Tyr (YPYY) 
Casoxin C, κ-cn f(25-34) Tyr-Ile-Pro-Ile-Gln-Tyr-Val-Leu-Ser-Arg (YIPIQYVLSR) 
serorphin, BSA f(399-404) Tyr-Gly-Phe-Asn-Ala (YGFNA) 
Bovine Blood  
hemorphin-4, β-chain of bovine haemoglobin, f(34-37) Tyr-Pro-Trp-Thr (YPWT) 
hemorphin-5, β-chain of bovine haemoglobin, f(34-38) Tyr-Pro-Trp-Thr-Gln (YPWTQ) 
hemorphin-7, β-chain of bovine haemoglobin, f(34-40) Tyr-Pro-Trp-Thr-Gln-Arg-Phe (YPWTQRF) 
LVV-hemorphin-7, β-chain of bovine haemoglobin, 
f(31-40) 
Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg-Phe  
(LVVYPWTQRF) 
V-hemorphin-5 hemorphin-7, β-chain of bovine 
haemoglobin, f(34-40) 
Val-Tyr-Pro-Trp-Thr-Gln (VYPWTQ) 
VV-hemorphin-7, β-chain of bovine haemoglobin, f(32-
40) 
Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg-Phe (VVYPWTQRF) 
Human milk  
Casoxin D, αS1-cn f(158-164) Tyr-Val-Pro-Phe-Pro-Pro-Phe (YVPFPPF) 
β-casomorphin (1–4), β-cn f(51-54) Tyr-Pro-Phe-Val (YPFV) 
β-casomorphin (1–5), β-cn f(51-55) Tyr-Pro-Phe-Val-Glu (YPFVE) 
β-casomorphin (1–7), β-cn f(51-57) Tyr-Pro-Phe-Val-Glu-Pro-Ile (YPFVEPI) 
β-casomorphin (1–8), β-cn f(51-58) Tyr-Pro-Phe-Val-Glu-Pro-Ile-Pro (YPFVEPIP) 
β-casorphin (1–4), β-cn f(41-44) Tyr-Pro-Ser-Phe (YPSF) 
Goat milk  
αS1-cn f(90-95) variant B Arg-Tyr-Leu-Gly- Tyr-Leu (RYLGYL) 
αS1-cn f(90-96) variant B Arg-Tyr-Leu-Gly- Tyr-Leu-Glu (RYLGYLE) 
αS1-cn f(91-96) variant B Arg-Tyr-Leu-Gly- Tyr-Leu-Glu (YLGYLE) 
κ-cn f(25-34) Tyr-Ile-Pro-Ile-Gln-Tyr-Val-Leu-Ser-Arg (YIPIQYVLSR) 
κ-cn f(33-38)  Ser-Arg-Tyr-Pro-Ser-Tyr (SRYPSY) 
κ-cn f(35-38) Tyr-Pro-Ser-Tyr (YPSY) 
κ-cn f(35-41) Tyr-Pro-Ser-Tyr-Gly-Leu-Asn (YPSYGLN) 
κ-cn f(56-61) Leu-Pro-Tyr-Pro-Tyr-Tyr (LPYPYY) 
κ-cn f(58-61) Tyr-Pro-Tyr-Tyr (YPYY) 
κ-cn f(56-61) variant J Leu-Pro-Tyr-Pro-Tyr-Cys (LPYPYC) 
κ-cn f(58-61) variant J Tyr-Pro-Tyr-Cys (YPYC) 
Sheep milk  
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Origin Structure 
β-casomorphin 8, β-cn f(60-67) Tyr-Pro-Phe-Thr-Gly-Pro-Ile-Pro (YPFTGPIP) 
Buffalo milk  
β-casomorphin 7, β-cn f(60-66) Tyr-Pro-Phe-Pro-Gly-Pro-Ile (YPFPGPI)  
Cereal   
Gluten exorphin A4  Gly-Tyr-Tyr-Pro (GYYP) 
Gluten exorphin B4  Tyr-Gly-Gly-Trp (YGGW) 
Gluten exorphin A5  Gly-Tyr-Tyr-Pro-Thr (GYYPT) 
Gluten exorphin B5  Tyr-Gly-Gly-Trp-Leu (YGGWL) 
Gliadorphin 7 (also known as gluteomorphin)  Tyr-Pro-Gln-Pro-Gln-Pro-Phe (YPQPQPF) 
Gluten exorphin C5 Tyr-Pro-Ile-Ser-Leu (YPISL) 
Vegetable   
Rubiscolin-5  Tyr-Pro-Leu-Asp-Leu (YPLDL) 
Rubiscolin-6  Tyr-Pro-Leu-Asp -Leu-Phe (YPLDLF) 
Soymorphin 5 Tyr-Pro-Phe-Val-Val (YPFVV) 
  
Adapted from Meisel and FitzGerald, 2000; Yang et al., 2001; Teschemacher, 2003; Chessa 
et al. 2008. 
2.2.1 Bioinformatic screening  
Using a bioinformatics approach it is possible to identify other potential biological precursors 
for opioid peptides. For this review the NCBI RefSeq (http://www.ncbi.nlm.nih.gov/ accessed 
October 2008) and the Swiss-Prot (http://www.ebi.ac.uk/swissprot/ accessed October 2008) 
databases were searched for protein precursors which contain the following exogenous opioid 
peptides sequences: 
 - YPFPG:  β-casomorphin 5 
 - YPFP:  β-casomorphin 4 
 - YPFVV:  Soymorphin 5 
 - YGGWL:  Gluten exorphin B5 
 - YPLDLF: Rubiscolin 6 
The results of this bioinformatic search are presented in Table 3. This table does not include 
the well known food proteins summarized in Table 2. 
Table 3: Summary of bioinformatic search for less common parent protein precursors 
containing selected opioid peptide sequences. 
Organism Function or Name Sequence Reference 
YPFPG (β-casomorphin 5) 
Synechococcus Enzyme (173)-YPFPG-(177) Swissprot, 
 Q2JK10, Q2JY06 
Mus musculus 
Homo sapiens (Human) 
 (452)-YPFPG-(455) Swissprot 
Q8K243, Q6AZZ1 
E. coli Oxido-reductase (398)-YPFPG-(402) Swissprot  
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P37906 
Canis familiaris (Dog). 
Homo sapiens (Human). 
Glycogen-
debranching enzyme 
(50)-YPFPG-(54) Swissprot 
P35573, Q2PQH8 
Oryctolagus cuniculus 
(Rabbit). 
Glycosyltransferase (73)-YPFPG-(77) Swissprot 
P35574 
Homo sapiens (Human). Protein Kinase (100)-YPFPG-(104) Swissprot 
P49842 
YPFP (β-casomorphin 4) 
Saccharomyces 
cerevisiae  
Putative 
uncharacterized 
protein 
 
oligosaccharyl 
transferase 
(76)-YPFP-(79) 
 
 
 
(338)-YPFP-(341) 
Swissprot 
P87283 
 
 
P48439 
Homo sapiens (Human). Transmembrane 
protein 
(143)-YPFP-(146) Swissprot 
Q5BJD5 
Gallus gallus (Chicken) Transmembrane 
protein 
(121)-YPFP-(124) Swissprot 
Q5ZIL6 
Homo sapiens (Human) 
Mus musculus 
Tenascin (1978)-YPFP-(1981) 
(1887)- YPFP-
(1890) 
Swissprot 
P24821, Q80YX1 
Drosophila 
melanogaster 
Protein split ends (1708)-YPFP-(1711) Swissprot 
Q8SX83 
Salmo salar  
(Atlantic salmon) 
Probable signal 
peptidase complex 
subunit 2 
(80)-YPFP-(83) NCBI 
ACI69108 
Homo sapiens (Human). rna exonuclease (944)-YPFP-(947) Swissprot 
Q8N1G1 
Bos taurus (Bovine). Lipid transport (105)-YPFP-(108) Swissprot 
P02720 
YPFVV (Soymorphin) 
Homo sapiens (Human). 
Mus musculus 
Mismatch repair 
endonuclease 
(318)-YPFVV-(322) Swissprot 
P54278, P54279 
Gibberella zeae FACT complex 
subunit POB3 
(305)-YPFVV-(309) Swissprot 
Q4IJU0 
Arabidopsis thaliana Serine/threonine-
protein kinase 
(1872)-YPFVV-
(1876) 
Swissprot 
Q9FKS4 
Gallus gallus (Chicken) Aprataxin (59)-YPFVV-(63) Swissprot 
P61798 
YGGWL (Gluten exorphin B5) 
Homo sapiens (Human). 
Mus musculus 
Rattus norvegicus 
Myosin phosphatase 
Rho-interacting 
protein 
(46)-YGGWL-(50) Swissprot 
Q6WCQ1, P97434, Q9ERE6 
Arabidopsis thaliana Sugar transport 
protein 
(461)-YGGWL-(465) Swissprot 
Q8L7R8 
YPLDLF (Rubiscolin 6) 
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Vitis vinifera Ribulose 
bisphosphate 
carboxylase large 
chain 
(103)-YPLDLF-(108) Swissprot P56648 
Synechococcus sp. 
Spinacia Oleracea 
Ribulose 
bisphosphate 
carboxylase large 
chain 
(95)-YPLDLF-(100) 
(103)-YPLDLF-(108) 
Swissprot Q0I8Q2, P00875 
Solanum tuberosum Ribulose 
bisphosphate 
carboxylase large 
chain 
(103)-YPLDLF-(108) Swissprot P25079 
 
As can be seen from Table 3, sequences corresponding to opioid peptides were found in 
diverse proteomes from animals, humans, microbes and plants. The significance of the 
presence of opioid peptides in these proteomes is unclear. However, given the right hydrolytic 
conditions the human proteome itself could act as a source of peptides which interact with the 
opioid system. For opioid sequences detected in proteomes other than the human proteome, it 
is necessary to take into account the presence of these proteins in food derived from these 
organisms (e.g. salmon, chicken, Saccharomyces cerevisiae) and the proteolytic system 
involved in their breakdown.  
2.3 Significance of genetic polymorphism to the release of opioid peptides 
from β-casein 
The primary sequence of all food proteins is subject to genetic variation. This is true also in 
the case of bovine milk proteins. Furthermore, genetic polymorphism may dictate the type of 
bioactive peptides released from milk proteins. For example, in β-casein an amino acid 
substitution occurs at position 67 in different variants 
…-Tyr60-Pro61-Phe62-Pro63-Gly64-Pro65-Ile66-(His67)-… β-casein A1 and B variants 
…-Tyr60-Pro61-Phe62-Pro63-Gly64-Pro65-Ile66-(Pro67)-… β-casein A2 variant 
In β-casein A1 and B variants histidine occurs in position 67, whereas in β-casein A2 proline is 
present in the same position. 
This genetic substitution of histidine with proline has been reported to prevent the enzymatic 
hydrolysis of the peptide bond between residues 66 and 67 in β-casein A2 thereby preventing 
the release of BCM7 (β-casein f(60-66)) from β-casein A2. (Hartwig, 1997; Jinsmaa et al., 
1999) 
Since genetic polymorphism is breed related, much interest has focused on characterising β-
casein variability in bovine populations, particularly when looking at possible health effects of 
BCMs. 
The first evidence of genetic polymorphism in β-casein came from Aschaffenburg (1961) 
while studying milk from Jersey and Guernsey cows. Using paper electrophoresis in the 
presence of 6.0 M urea in citrate-phosphate buffer pH 7.5, he reported that β-casein existed as 
three polymorphs, designated in order of decreasing mobility as β-casein A, B and C. 
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Subsequently, Peterson and Kopfler (1966), using acid urea polyacrylamide gel 
electrophoresis discovered that β-casein A could be separated into three additional variants, 
now known as β-casein A1, A2 and A3. These variants differ from each other by the number of 
positively charged His residues in the primary sequence, i.e., 6, 5 and 4, respectively. More 
recently, the application of chromatographic separation, isoelectric focusing and DNA-based 
techniques has led to the discovery of a range of other β-casein polymorphs. The specific 
amino acid substitutions which distinguish some of the different β-casein variants are 
summarised in Table 4.  
 
Table 4: Amino acid substitutions in some genetic polymorphs of bovine β-casein (adapted 
from Ng-Kwai-Hang and Grosclaude, 2003). 
Variant Amino acid position, amino acid  substitution 
A1 → A2 67 His → Pro 
A2 → A3 106 His → Gln 
A1 → B 122 Ser → Arg 
A1 → C 37 Glu → Lys  35 SerP → Ser 
A2 → D 18 SerP → Lys 
A2 → E 36 Glu → Lys 
 
Numerous studies have been performed on the allele frequency distributions of the three main 
species of the genus Bos, i.e. Bos taurus (taurines), Bos indicus (zebu) and Bos grunniens 
(yak). However, to date most studies have been performed on taurines as they are the main 
milk producing cattle breed in the Western world. A non-exhaustive summary of the reported 
breed and country related frequency distributions for taurine β-caseins is outlined in Table 5.  
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Table 5: Summary of β-casein allele frequency distribution in selected Western cattle breeds. 
β-Casein Allele Frequency Breed No.  Animals 
A1 A2 B Other 
Reference 
Angus 77 (USA) 0.95  0.05  Caldwell et al., 1971 
Ayrshire 45 (USA) 0.72 0.28   Kiddy et al., 1966 
Ayrshire 29 (UK) 0.60 0.40   Aschaffenburg, 1968 
Ayrshire ? (Canada) 0.60 0.40   Ng-Kwai-Hang and Kim, 1994 
Ayrshire 37 (N. Zealand) 0.432 0.527   Winkelman and Wickham, 
1997 
Ayrshire 20,990(Finland) 0.509 0.490 0.001  Ikonen et al., 1996 
Ayrshire 46 (Finland) 0.50 0.50   Lien et al., 1999 
Black Pied 140 (Estonia) 0.97*  0.03  Pupkova, 1980 
Braham 59 (USA) 0.99*  0.01  Caldwell et al., 1971 
Brown Italian 298 (Italy) 0.11 0.69 0.18 0.02 Boettcher et al., 2004 
Brown Swiss ? (Canada) 0.32 0.52 0.16  Ng-Kwai-Hang and Kim, 1994 
Brown Swiss 22 (USA) 0.14 0.66 0.18 C: 0.02 Kiddy et al., 1966 
Brown Swiss 50 (USA) 0.18 0.66 0.16  Van Eenennaam and 
Medrano, 1991 
Canadienne ? (Canada) 0.58 0.34 0.08  Ng-Kwai-Hang and Kim, 1994 
Dutch-Fr 10151 (Holland) 0.766 0.147 0.014 B:0.073 Bovenhuis and van 
Arendonk, 1991 
Finncattle 
(EFC) 
31 (Finland) 0.274 0.710 0.016  Lien et al. 1999 
Finncattle 
(NFC) 
26 (Finland) 0.385 0.615   Lien et al. 1999 
Finncattle 
(WFC) 
41 (Finland) 0.293 0.671 0.037  Lien et al. 1999 
Friesian(Fr) 3761 (N. Zealand) 0.465 0.510   Winkelman and Wickham, 
1997 
Friesian(Fr) 347 (Italy) 0.38 0.55 0.07  Boettcher et al., 2004 
Grey 120 (Hungary) 0.23 0.76 0.01  Baranyi et al., 1993 
Guernsey 196 (USA) 0.01 0.98 0.02  Aschaffenburg, 1963 
Guernsey 40 (USA)  0.96  C:0.04 Van Eenennaam and 
Medrano, 1991 
Hereford 48 (USA) 0.75*  0.25  Caldwell et al., 1971 
Holstein 260 (Australia) 0.63 0.35 0.02  McLean et al., 1984 
Holstein 1383 (Italy) 0.58 0.40 0.02  Aleandri et al., 1997 
Holstein 1152 (USA) 0.43 0.55 0.02  Van Eenennaam and 
Medrano, 1991 
Holstein-Fr 85 (UK) 0.66 0.24 0.06 A3:0.04 Aschaffenburg et al., 1968 
Holstein-Fr 87 (Germany)  0.960 0.040  Aschaffenburg et al., 1968 
Holstein-Fr 6460 (Canada) 0.54 0.44 0.01 A3:0.01 Hines et al., 1977 
Holstein-Fr 6575 (USA) 0.42 0.53 0.02 A3:0.03 Hines et al., 1977 
Holstein-Fr 260 (USA) 0.624 0.347 0.025 A3:0.004 McLean et al., 1984 
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β-Casein Allele Frequency Breed No.  Animals 
A1 A2 B Other 
Reference 
Holstein-Fr 920 (Canada) 0.363 0.632 0.001 A3:0.004 Lin et al., 1986 
Holstein-Fr 696 (Ireland) 0.72 0.25 0.03  O’ Hara, 1995 
Holstein-Fr 43 (Finland) 0.430 0.523 0.047  Lien et al. 1999 
Holstein-Fr 143 (Poland) 0.402 0.598   Kaminski et al., 2007 
Icelandic 44 (Iceland) 0.326 0.674   Lien et al., 1999 
Jersey 37 (USA) 0.22 0.49 0.29  Kiddy et al., 1966 
Jersey  47 (UK) 0.09 0.63 0.28  Aschaffenburg, 1968 
Jersey 308 (Australia) 0.07 0.57 0.36  McLean et al., 1984 
Jersey 157 (Denmark) 0.07 0.58 0.35  Bech and Kristiansen, 1990 
Jersey 172(USA) 0.17 0.50 0.33  Van Eenennaam and 
Medrano, 1991 
Jersey ? (Canada) 0.19 0.50 0.31  Ng-Kwai-Hang and Kim, 1994 
Jersey 116 (Ireland) 0.30 0.41 0.28 A3 : 
0.01 
O’ Hara, 1995 
Jersey 1328 (N. Zealand) 0.123 0.591   Winkelman and Wickham, 
1997 
Kerry 123 (Ireland) 1.00*    Murphy and Downey, 1969 
Kerry 41 (Ireland) 0.24 0.76   O’ Hara, 1995 
Normande 155 (France) 0.21 0.32 0.45 A3: 0.02 Aschaffenburg, 1968 
Norwegian 38(Norway) 0.513 0.487   Lien et al., 1999 
Red Danish 169 (Denmark) 0.71 0.23 0.06  Bech and Kristiansen, 1990 
Shorthorn 40(USA) 0.49 0.49 0.02  Van Eenennaam and 
Medrano, 1991 
Simmental 2626 (Denmark) 0.231 0.673 0.082 C : 
0.013 
Baranyi et al., 1993 
Simmental 621(Croatia) 0.190 0.630 0.150  Curik et al., 1997 
SLB 43(Sweden) 0.407 0.593   Lien et al., 1999 
SLB 42 (Sweden) 0.34 0.60 0.06  Hallén et al. 2008 
Spotted 101 (Hungary) 0.21 0.715 0.06 C : 
0.015 
Baranyi et al., 1993 
SRB 394(Sweden) 0.460 0.531 0.008  Lunden et al., 1997 
SRB 39(Sweden) 0.397 0.603   Lien et al., 1999 
SRBH 39 (Sweden) 0.44 0.55 0.01  Hallén et al. 2008 
SRBL 35 (Sweden) 0.36 0.63 0.01  Hallén et al. 2008 
White Danish 223 (Denmark) 0.55 0.39 0.03 A3 : 
0.03 
Bech and Kristiansen, 1990 
* the β-casein A genetic variants were not distinguished into A1, A2 and A3 variants 
? number of animals in study not given; EFC – Eastern Finncattle; NFC – Northern 
Finncattle; WFC – Western Finncattle 
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As can be seen from Table 5, the most commonly occurring β-casein variants in Western 
cattle breeds are A1, A2 and B. Country related differences in the β-casein allele frequencies 
are observed which may be reflective of local breeding policies, some cross-breeding and 
most importantly targeted breeding for increased milk production traits. Some interesting 
trends arise from the data. For example, Jersey, Normande and Simmental breeds appear to 
consistently have a relatively low frequency of occurrence of β-casein A1. In comparison with 
the other breeds listed in this table Jersey, Normande and Hereford have a relatively high 
frequency of occurrence of the B variant of β-casein. On the other hand, Guernsey cattle 
almost exclusively appear to have the β-casein A2 genotype. The Brown Swiss, Brown Italian, 
Hungarian Spotted and Gray breeds had a relatively higher occurrence of β-casein A2 
compared to A1 alleles. The relative distribution of β-casein A1 and A2 alleles in Holstein and 
Friesian breeds appears to be region/country specific with certain regions having a high level 
of  β-casein A1, others having high level of  A2 and others again having roughly similar allele 
frequency distributions for A1 and A2 (Table 5). 
However, it is important to take sample size into account, as in Table 5 where population 
sizes tested range from approximately 20 to 21,000 animals. 
2.4 Variation in β-casein variant frequency distribution as a function of 
time 
Data in Table 5 cover a 40-year period and give us a general view of the allele frequency 
distribution in different cattle breeds only at the respective time of analysis. It is thus difficult 
to draw definitive conclusions on the relative distribution of β-casein variant proteins in milk 
for a given consumer population at any given time.  
Breeding of bovine cattle has been ongoing in Europe for centuries with the objective to 
increase both carcass weight and milk yield. As an example, in the Nordic countries milk 
yield has increased significantly between 1985 and 1997 (van Arendonk and Liinamo, 2003) 
and correspondingly a significant change in the breed composition of national herds has taken 
place. Comparative data are available for Finland, where before the 1960’s milk production 
was largely based on Finncattle (Northern, Eastern and Western) while nowadays it is mainly 
from Finnish Ayrshire and Finnish Holstein-Friesian (Liinamo, 2000). Similarly, the breed 
composition of the milk-producing cattle in other European countries has changed during the 
same time period. 
Therefore, given the β-casein allele frequency distribution differences between breeds (Table 
5) it may be assumed that in countries where herd composition has changed over the years 
there have been corresponding changes in the β-casein variant composition in the milk. 
However, in certain countries such as Iceland, where the importation of foreign cattle breeds 
has not been allowed, it may be assumed that the breed composition of the milk producing 
cattle has not changed significantly in the same way. Genetic variation in such cases is also 
possible, though expectably slower, due to the selection practices employed within the breed 
to maintain or improve its traits. However, to our knowledge no direct data is available about 
changes in the β-casein variant composition of milk in Icelandic cattle over time. 
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In addition, apart from some studies in selected Nordic countries in the late 1990’s (Lien et 
al., 1999; Elliott et al., 1997, Thorsdottir et al., 2000, Iggman, 2003) we do not have any  
specific Europe wide information on the β-casein variant composition of bulk milk currently 
produced in Europe. 
With globalisation in the marketplace we have little direct information or indeed control over 
the origin of the milk proteins in market milk, in fermented dairy products or in formulated 
foods incorporating milk protein ingredients. Therefore, the protein variant composition of 
milk and milk ingredients, and the overall level of intake of specific milk protein variants by 
different populations is currently unknown. 
2.5 Polymorphism in human milk 
Human milk varies in protein content ranging from 1.4 – 1.6 g/100 ml during early lactation 
and declining to about 0.7 – 0.8 g/100 ml at 6 months of lactation (Lönnerdal et al., 1976; 
Kunz et al., 1992). The proportion of casein to total protein in human milk ranges from 10% 
at early lactation to approximately 40% in mature milk (Kunz and Lönnerdal, 1990; 1992). 
The overall composition of human milk is dependent on the stage of lactation along with 
specific variations in the mother’s genotype. β-casein is the major casein component in human 
milk (Greenberg et al., 1984) however, κ- (Brignon et al., 1985) and αS1-casein are also 
present in low amounts (Cavaletto et al., 1994; Rasmussen et al., 1995). Very little appears to 
be known about genetic variation in human milk caseins. However, the results of Dev et al. 
(1994) as interpreted by Steinerova et al. (2004) seem to indicate that human milk does not 
contain β-casein A1.  
3 OPIOID PEPTIDES IN FOOD AND THEIR FORMATION DURING DIGESTION 
In the scientific literature many papers deal with the occurrence of opioid peptides in dairy 
foods prior to or after simulated gastrointestinal digestion (SGID). The data reported has been 
obtained using analytical techniques, including liquid chromatography (LC) as a peptide 
separation technique with UV detection and/or mass spectrometry (MS) for identification and 
quantification of BCMs. Different digestion protocols employing one or more gastric and 
intestinal proteinases have been used for the release of BCMs. It is evident that the approach 
used for isolation, identification and quantification of BCMs impacts on the reliability and the 
usefulness of results. Furthermore, additional uncertainty arises from the published data 
depending on whether real or model dairy food systems were used. 
The theoretical yield of different opioid peptides per gram of precursor protein is summarised 
in Table 6. 
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Table 6: Precursor proteins and theoretical yield for some opioid agonist and antagonist 
peptides derived from cow milk proteins (adapted from Meisel and FitzGerald, 2000) 
Bioactive peptide Sequence 
 
Precursor 
Protein 
Maximum 
theoretical yield 
(mg/g protein) 
Opioid agonists    
BCM7 YPFPGPI f(60-66) β-cn 33.0 
BCM5 YPFPG f(60-64) β-cn 24.2 
αs1-Casein exorphin RYLGYLE f(90-96) αs1-cn 38.7 
α-Lactorphin YGLF f(50-53) α -la  35.2 
β-Lactorphin YLLF f(102-105) β-lg 30.2 
Serorphin YGFNA f(399-404) BSA 10.5 
Opioid antagonists    
Casoxin A YPSYGLNY f(35-42) κ-cn  51.4 
Casoxin B YPYY f(58-61) κ-cn 31.8 
Casoxin C YIPIQYVLSR f(25-34) κ-cn 65.8 
 
3.1 Peptides presence in food 
3.1.1 Human milk 
There are a limited number of reports on opioid peptides identified in human milk. These 
peptides were initially studied by Brantl et al. (1984) and Koch et al. (1985) and more 
recently by Ferranti et al. (2004). Using MALDI/TOF/MS and ESI/MS Ferranti et al. (2004) 
reported that human milk casein was more susceptible to proteolysis than bovine milk casein. 
Most of the low and medium molecular weight peptides in human milk collected during the 
first week of lactation originated from the endogenous hydrolysis of β-casein. Two opioid 
peptides corresponding to β-casomorphin (1–8) and β-casorphin (1–4) were identified. These 
authors further reported that the size of the peptides decreased as a function of increasing 
gestation and lactation period. In fact, while larger precursors fragments of BCMs (51–73, 
48–73 and 35–73) were present both  in preterm and normal term milk, the shorter sequences 
(including β-casomorphin 1–8) were only detected in milk from women delivering after the 
normal gestation period (39 and 40 weeks). 
Using an HPLC/UV methodology, Jarmolowska et al. (2007a) determined the content of 
endogenous BCM5 and BCM7 in human milk during different stages of lactation. They 
reported that the BCM content decreased during the progression of lactation. They also 
reported that the BCM content of colostrum was five times higher for BCM5 and eight times 
higher for BCM7 compared to the content of these peptides in mature milk. The BCM5 and 
BCM7 levels in colostrum were in the range from 0.00 to 19.77 μg/mL and 0.00 to 26.78 
μg/mL, respectively. In mature milks (2 and 4 months after delivery) the levels ranged from 
zero to 10.56 μg/mL and 0.00 to 2.84 μg/mL for BCM5 and BCM7, respectively. 
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3.1.2 Bovine milk 
One study reports the presence of BCM7 in unprocessed bovine milk (Cieslinska et al., 2007). 
Other studies confirming these findings are not available in the literature. The identification 
was performed using HPLC/UV methodology, and the health status of the animals from 
which the milk was derived was not reported. Somatic cells in milk are a normal phenomenon 
and their count increases dramatically during clinical and also sub-clinical mastitis.  
Increasing somatic cell count (SCC) is associated with increasing proteolysis of caseins. 
Therefore, the enhanced proteolytic activity in animals having a high SCC may contribute to 
the release of BCMs or their precursors. The specificity and activity of cathepsins and elastase 
derived from SCCs have been studied in model systems but the actual levels of secretion of 
these enzymes in milk itself have not been reported. The activity of cathepsin B found in 
lysosomes of somatic cells is significantly correlated with the SCC of milk and it has been 
shown that it partially survives conventional pasteurisation (O’Driscoll et al., 1999). 
Considine et al. (2004), studied in vitro digestion of β-casein and found that the activity of 
cathepsin B was similar to or identical to that of plasmin and cell envelope proteinases (CEP) 
produced by a number of Lactococcus lactis strains. Furthermore, cathepsin B was reported to 
be able to release BCM10 (f60–69). Wedholm et al. (2008) studied the activities of enzymes 
released from somatic cells in a milk sample containing > 500.000 cells/mL corresponding to 
sub-clinical Streptococcus uberis mastitis. The results indicated that cathepsins and elastase 
were associated with β-casein proteolysis, however, release of BCMs was not observed. 
Using MALDI MS and MS/MS, Napoli et al. (2007) studied the activity of the endogenous 
proteinases during 24- to 216-h incubation at 37 °C at both physiological and acid pH values 
in unprocessed milk produced from each quarter of the mammary gland of a healthy cow 
(SCC=0.6-1.3 x 103) and a mastitic cow (SCC=0.4-11.6 x 106). They identified β-casein 
derived peptides indicating cleavage sites located toward the C-terminus of the protein but no 
hydrolysis appeared to occur in the BCM region. Proteinases of somatic cells may also be 
involved in proteolysis of β-casein during storage of UHT milk, since no study to date has 
demonstrated thermal inactivation of these enzymes during industrial UHT processing of 
milk. 
According to Gaucher et al. (2008), β-casein appeared to be hydrolyzed in UHT (140 °C for 4 
sec) treated milk following storage at 20 °C for 6 months. Using LC-MS/MS, they identified 
different pro-BCMs (f54–68, f54–69, f55–65, f55–68, f57–68) resulting from the hydrolytic 
action of cathepsin B, cathepsin G and elastase on β-casein. 
3.1.2.1 Fermented milk 
A number of studies have reported on the formation and fate of BCM7 in fermented dairy 
products, including cheese, fermented milk and yoghurt. However, only a few detail the actual 
level of BCM7 in these dairy products. The lack of quantifiable data arises from the difficulty 
in identifying and quantifying BCMs in such complex food matrices which are comprised of 
many peptides as a result of milk protein hydrolysis. The formation/degradation of BCM7 has 
been mainly studied using purified caseins or synthetic BCMs as substrates and single 
bacterial strains or their associated proteinase/peptidase systems. 
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Hamel et al. (1985) were the first to identify β-casomorphin immunoreactive material in 
cow’s milk following incubation with various bacterial species, including lactic acid bacteria 
(LAB). The proteolytic systems in LAB involve both CEP and intracellular peptidases; the 
former being responsible for releasing different oligopeptides from intact milk protein 
molecules which are further hydrolysed by the peptidases into shorter fragments and free 
amino acids. Recent studies with 21 Lactobacillus strains isolated from fermented milks have 
demonstrated that these LAB were able to degrade 80–90% of the β-casein following 72-96 h 
in vitro incubation of a sodium caseinate solution (Tzvetkova et al., 2007). Similar findings 
were recorded for LAB proteinases from Lactococcus lactis subsp. cremoris Wg2 which 
hydrolysed approximately 40% of the peptide bonds in β-casein resulting in more than 100 
oligopeptides (Mierau et al., 1997; Juillard et al., 1995). 
In general, the formation of casomorphins in dairy products fermented with LAB has been 
considered unlikely given that these bacteria have a high intracellular X-prolyldipeptidyl 
aminopeptidase (PepX) activity (Gobbetti et al., 2002). PepX is the best characterized proline-
specific enzyme produced by LAB and it releases x-Pro dipeptides from the N-terminus of 
peptides. Hydrolysis with PepX would remove the X-Pro sequence which is central for the 
bioactivity of BCM7. According to Matar and Goulet (1996), the cell-free extracts of the wild 
type or PepX-deficient mutant strains of Lactobacillus helveticus L89 totally or partially 
hydrolyse synthetic BCM7 into BCM4 after incubation at 37°C for 120 min. Using LC/MS, 
the authors also reported the formation of BCM4 but not BCM7 in a pasteurized (65 °C for 30 
min) milk fermented with a PepX-deficient mutant of Lactobacillus helveticus L89. 
According to Stepaniak et al. (1995), BCM7 inhibits the in vitro activity of peptidases (PepO 
and PepN) from Lactococcus lactis ssp. lactis MG1363. However, the PepX activity of the 
same microorganism was not inhibited by this peptide and PepX was actually reported to 
hydrolyse BCM7. Muehlenkamp et al. (1996) evaluated the susceptibility of synthetic BCM3, 
-5 and -7 to the proteolytic system of a commercial strain of Lactococcus cremoris. They 
reported after 6-15 weeks of incubation that BCM7 was more resistant to proteolysis than 
BCM3 and BCM5.  
The type of starter used seems to affect the nature of the bioactive peptides released in 
fermented milks. It is well known that Lb. delbrueckii subsp. bulgaricus and S. thermophilus, 
which are used in combination as a starter in yoghurt manufacture, release peptides that 
promote the growth of the mixed culture. In general, due to the short fermentation time, lysis 
of cells of LAB is unlikely and intracellular peptidase activity is unlikely to significantly 
contribute to proteolysis during yoghurt manufacture (Meisel and Bockelmann, 1999). As 
reported by Donkor et al. (2007), most of the proteolytic activity in yoghurt containing L. 
delbruekii ssp. bulgaricus Lb1466 and S. thermophilus St1342 occurs during the first 24 h 
following manufacture and subsequently continues to increase at a slower rate during storage 
(28 d) at 4 °C. However, according to Schieber and Brückner (2000), storage at 4 °C for 3 
weeks resulted in extensive proteolysis of milk proteins in yoghurt made from skimmed milk 
heated to 90 °C and fermented (44 °C for 3 h) using the above two LAB strains. In this 
product, the majority of the peptides arose from β-casein A1 breakdown but only peptides, 
including BCM containing sequences (i.e. β-casein 57-68 and β-casein 57-72), were identified 
by means of HPLC-MS and peptide sequencing. Kahala et al. (1993) investigated the peptides 
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released from several Finnish fermented milk products, including two yoghurts, produced 
with a mixed starter culture of L. bulgaricus and S. thermophilus. Most of the peptides 
identified originated from either the N- or C-terminal region of β-casein, however no BCMs 
were found. 
According to Donkor et al. (2007), proteolysis in fermented milk containing both yoghurt 
starter culture and probiotic organisms (L. acidophilus L10, L. casei L26 and B. lactis B94) 
was significantly higher as compared to the milk fermented with the yoghurt culture only. 
Using in vitro tests, Shihata and Shah (2000) reported that extracts containing proteolytic 
systems of yoghurt bacteria (S. thermophilus and L. delbrueckii ssp. bulgaricus) were highly 
proteolytic compared to those from probiotic bacteria (L. acidophilus and Bifidobacterium 
spp.). It appears that the use of probiotic strains for production of fermented milk influences 
the peptide profile in the final product. Furthermore, the potential release of BCMs during 
gastrointestinal digestion may also be affected by the peptide profile. In this regard, a UHT 
(142 °C for 3-4 sec) milk fermented with the probiotic Lactobacillus GG strain which milk 
was subsequently digested with pepsin and trypsin was found to contain peptide sequences 
similar to BCM11 (derived from β-casein A2) and BCM4 (Rokka et al., 1997). These peptides 
were not present in the fermented milk prior to pepsin and trypsin digestion. 
3.1.2.2 Cheese 
The formation and fate of BCM7 have been studied in different cheese varieties which are 
considered a very complex food system. The extent and the pattern of proteolysis in cheese 
varies as a function of heat treatment of milk (unprocessed or pasteurized), type of coagulant 
(animal or vegetable), curd handling (cooking, salting, pH at draining), starter culture and 
ripening conditions (pH, time, temperature, humidity, secondary microflora). Most of the 
proteolysis occurs during ripening and as a result caseins are hydrolysed by endogenous 
proteinases, coagulant, and starter and non-starter proteinases. Moreover, as previously 
mentioned, BCM7 or related sequences produced by either endo- or exogenous enzymes may 
exert an inhibitory effect on intracellular peptidases of LAB (Stepaniak et al., 1995). All the 
above factors influence BCM7 release/degradation which therefore must be quantified under 
real cheesemaking conditions. In this regard, the action of the retained chymosin itself is not 
expected to release BCMs in cheese, irrespective of the pH value and salt concentration of 
cheese (McSweeney, 2004). 
Furthermore, proteolysis induced by plasmin does not lead to formation of known bioactive 
peptides (McSweeney, 2004). As already mentioned, both starter and non starter LAB 
proteinases/peptidases may hydrolyse proline-rich peptides, such as BCMs, which may be 
formed upon the action of proteolytic systems present in the cheese milk/curd. As peptidase 
activity is intracellular in LAB, it is likely that LAB peptidases contribute to protein 
hydrolysis only after cell lysis which generally occurs during cheese ripening (Meisel and 
Bockelmann, 1999). Additional proteolysis may be brought about by the action of fungal 
enzymes involved in the ripening of certain cheese varieties. Despite the fact that the 
mechanisms of action of most of the proteinases present in cheese are well elucidated, it is not 
possible to predict the formation/degradation of BCM7 in cheese. Only very few studies 
report on the presence and levels of BCM7 in cheeses. Jarmolowska et al. (1999), using 
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amino acid composition analysis reported BCM7 as being most likely present in extracts from 
Brie cheese samples. This peptide occurred in amounts ranging from 5 to 15 mg/kg cheese 
following different (not specified) maturation times. Previously, Muehlenkamp et al. (1996) 
reported no detectable amounts of BCM7 in the same cheese variety. HPLC separation 
coupled to UV detection was used for identification and quantitation of BCM7. In addition, 
BCM7 was not detected in other cheese varieties having different extents of proteolysis: 
Cheddar, Swiss type (60 day ripened), Blue and Limburger. Therefore, to date no data 
concerning the actual amounts of BCM7 in cheeses can be obtained from the literature.  
Muehlenkamp et al. (1996) reported that BCM7 was almost resistant to degradation by the 
proteolytic system of Lactococcus cremoris. This was particularly the case at pH 5.0-5.2 and 
high sodium chloride concentration (5%) as employed in the in vitro enzymatic tests. At 
lower salt concentration (1.5%), BCM7 was partially (50%) or totally degraded after 15 
weeks at pH 5.0 or pH 5.2, respectively. Taking the pH value (5.0-5.1) and salt concentration 
(1.8-2.0%) of Cheddar cheese into consideration, BCM7 is expected to be degraded to some 
extent by the starter culture used in Cheddar cheese manufacture. Information is available 
about the formation of peptides in enzyme-modified Cheddar cheese. Using LC-MS/MS, 
Haileselassie et al. (1999) identified several potentially bioactive peptides, including BCM7, 
from an enzyme-modified Cheddar cheese (EMC) prepared using Neutrase®, a neutral 
protease produced from Bacillus subtilis. However, the actual level of BCM7 in the EMC was 
not reported. The same authors did not find BCM7 when the enzyme-modified cheese was 
prepared using a crude extract of L. casei isolated from a mild Cheddar cheese. The findings 
of Haileselassie et al. (1999) suggest the destructive action exerted by proline specific 
peptidases from LAB on BCM7 present in cheese. As discussed later, other studies report 
cheeses to contain peptides including the BCM7 sequence. According to Singh et al. (1997), 
the persistence of peptides such as BCM9 (β-casein 60-68) in Cheddar suggests that PepX 
from LAB has no or little activity in cheese, perhaps because it is unstable. 
Several studies indicate that different cheeses contain peptides incorporating the BCM7 
sequence. These peptides could act as BCM7 precursors during further digestion processes. 
Addeo et al. (1992) revealed the presence of long peptides (e.g. 20-21 residues) containing the 
BCM7 sequence in ripened (up to 15 months) Parmigiano Reggiano cheese. According to the 
authors, the presence of such peptides demonstrates the resistance of this β-casein region to 
further enzymatic degradation. It is noteworthy that in this type of cheese extensive casein 
breakdown occurs during ripening at the end of which about 20% of protein nitrogen is 
represented by free amino acids. Stepaniak et al. (1995) isolated the β-casein (58-72) peptide 
(from genetic variant Al) from the water-soluble extract of Cheddar and Jarlsberg cheeses.  
Both the 57-58 and 56-57 bonds of β-casein have been reported to be easily hydrolyzed by 
proteinases from LAB (Visser et al., 1991). The β-casein (58-72) peptide was also released 
during Crescenza ripening (Smacchi and Gobbetti, 1998). This peptide was apparently 
resistant to further degradation by enzymes present in cheese and it was not hydrolysed by 
PepO and PepN activities. As already mentioned, β-casein (58-72) is reported to selectively 
inhibit endopeptidase (PepO), general aminopeptidase (PepN), and PepX from Lc. Lactis ssp. 
lactis MG1363 (Stepaniak et al., 1995). BCM9 (from variant A1 of β-casein) and several 
peptides including the BCM7 sequence were found in Cheddar cheese by Singh et al. (1995 
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and 1997). BCM9 was also found in Gouda (8 months aged) by Saito et al. (2000). Using LC-
MS-TOF and LC-MS/MS, Toelstede et al. (2008) found BCM9 and BCM10 in the water-
soluble extract of a matured Gouda cheese. BCM9 was released from the A1 and A2 variants 
of β-casein whereas BCM10 was derived from the A1 variant. Pro-BCM9 and pro-BCM10 
peptides were liberated from both variants by cleavage of Gln56– Ser57, Ser57-Leu58 and Leu58-
Val59 bonds. 
The proteolytic systems potentially involved during manufacture and ripening of Emmental 
cheese were investigated by Gagnaire et al. (2001). Due to inactivation of coagulant by the 
high curd cooking temperature, CEP from thermophilic lactobacilli, chatepsin D and plasmin 
were mainly thought to be responsible for the hydrolysis of β-casein from which neither 
BCMs nor pro-BCMs were released. The role of bifidobacteria in releasing BCM3 and BCM5 
during ripening of Edam cheese was studied by Sabikhi et al. (2001) using HPLC/UV 
detection. Both Edam and probiotic Edam cheeses contained BCM3 whereas BCM5 was not 
present. Using LC-MS, Rizzello et al. (2005) analyzed the water-soluble extracts of Caprino 
del Piemonte, an Italian goat cheese. A peptide corresponding to β-CN f60–68 (YPFTGPIPN) 
was identified in the cheese extract. 
3.1.2.3 Infant formulas 
The potential occurrence of BCMs in commercial infant formulas has not been extensively 
studied. In the only study published to date, Jarmolowska (2007b) assayed for opioid activity 
in samples of “Humana” formula available on the Polish market. Four opioid peptides with 
agonistic or antagonistic activity were found in the peptide extract of this formula and its 
pepsin–trypsin hydrolysate. These peptides were identified as BCM5, casoxin C and 6 and 
lactoferroxin A. The opioid activity of the peptide extracts was determined by examining their 
influence on the motor activity of isolated rabbit intestine. The reported amounts (μg/mL) of 
these peptides in the peptide extract of Humana and its pepsin hydrolysate were as follows: 
BCM5 (0.39, 43.11), casoxin 6 (0.22, 6.21), casoxin C (0.075, 23.33) and lactoferroxin A 
(0.16, 11.40). Generally, the amounts of opioid peptides in the pepsin hydrolysate of 
"Humana" were significantly higher than in the non-pepsin treated sample. A recent paper 
using LC/MS reports no BCM5 or BCM7 in milk-based infant formulas (De Noni, 2008). 
3.1.3 Effect of milk processing on the release opioid peptides  
To our knowledge, no study has considered the effect of milk processing conditions on the 
release of BCMs during subsequent fermentation. It is well recognised that intense heat 
treatments (90-95 °C for 5-20 min) applied in yoghurt manufacturing can induce thermal 
modifications of protein contributing to the desired properties of the final product (i.e. 
viscosity, lack of syneresis). Heating causes unfolding of protein molecules and hence 
modifies their secondary and tertiary structure. In this regard, caseins are not as susceptible to 
severe heat denaturation compared to the globular whey proteins. Native β-casein appears to 
form only short lengths of α-helixes and has a less pronounced tertiary structure. For this 
reason, β-casein cannot or can hardly be denatured and its conformation is not expected to 
change much upon thermal treatment. 
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Schmelzer et al. (2007) studied the proteolysis of β-casein during peptic digestion under 
simulated gastro-intestinal digestion (SGID). No preferred pepsin cleavage sites were found 
on the basis of predicted secondary structure.  This finding supports the hypothesis that pepsin 
would most likely act in a similar manner on either the native or the heated forms of β-casein. 
Severe heat treatment of milk strongly enhances formation of β-lactoglobulin/κ-CN stable 
complexes on the surface of casein micelles. These complexes are believed to reduce casein 
proteolysis as they make the access of proteinases more difficult (Enright et al., 1999). The 
results obtained by Almaas et al. (2006) from digestion of both cows’ and goats’ milk with 
human gastric and duodenal juices showed that heated milk in general was more resistant to 
hydrolysis than unprocessed milk. 
Covalent interactions occurring upon heating involve both lactosylation and crosslinking 
within or between casein chains. These reactions can result in the formation of xenobiotic 
molecules some of which may be responsible for aggregation/polymerisation of β-casein 
molecules (Pellegrino et al., 1999). Deamidation and dephosphorylation of β-casein can occur 
when processing milk during yoghurt manufacturing (Van Boekel, 1999). The effect of these 
modifications of β-casein on its susceptibility to proteolysis during milk fermentation cannot 
be speculated. The role of thermal treatments in hindering or promoting BCM release from 
this protein molecule has not been elucidated, so far. 
To date, no study has been published concerning the effect of UHT treatment or in-bottle 
sterilisation on potential release of BCMs during digestion of heat-treated milk. Milk-based 
infant formulas are submitted to intense heat treatment during manufacture. Moreover, they 
contain dairy ingredients that in turn are usually obtained by industrial processing, including 
severe heat treatments. Therefore, heat damage can occur in the final infant formula and a 
diverse degree of protein modification could be expected. In the recent study of De Noni 
(2008), industrial indirect UHT treatments (156 °C for 6–9 sec) were not found to modify the 
release of BCM7 and, during SGID comparable amounts of peptides were formed from both 
raw formulations and heat-treated infant formulas.  
3.2 Peptide formation during in vitro simulated gastro-intestinal digestion 
(SGID) 
3.2.1 Milk derived opioids released in SGID 
The potential release of BCMs during gastrointestinal digestion of dairy products has been 
investigated in a number of studies. For this purpose, different protocols based on SGID have 
been adopted. The usefulness and reliability of these protocols depends on both enzymatic 
system and physiological factors adopted. Digestion process parameters, including the rate of 
gastric emptying and the changes in gastric pH value, are particularly relevant, especially in 
infants. In general, the use of hydrolytic enzyme preparations containing several amino and 
carboxyl peptidase formulations should lead to more reliable and comparable results as to 
what may happen during GI transit. Irrespective of the difference in protocols, it seems that an 
initial hydrolysis by pepsin plays a key role during SGID of β-casein as has been clearly 
elucidated by Jinsmaa et al. (1999). In this study, BCM9, -13 and -21 or (Val59)-BCMs were 
released after initial cleavage by pepsin of the Leu58-Val59 bond in β-casein followed by 
 Review of the potential health impact of β-casomorphins and related peptides 
 
 
EFSA Scientific Report (2009) 231, 31-107 
 
further degradation with intestinal proteinases. Very low levels of BCM7 (17 mmol 
BCM7/mol β-casein) were found in the elastase-leucine aminopeptidase digest of β-casein 
when the preliminary pepsin treatment at pH 2.0 was omitted. The role of pancreatic enzymes 
was also studied and no BCM7 was released when chymotrypsin or trypsin were used in place 
of pancreatin for β-casein digestion following pepsin treatment. Incubation with pepsin alone 
does not appear to release BCM7. 
Macaud et al. (1999) using second-order derivative spectra and UV-spectra comparison 
detected BCM3 but not BCM7 in a pepsin hydrolysate of casein. According to Schmelzer et 
al. (2007), the release of known bioactive peptides from the A1 or A2 variants of β-casein 
following peptic digestion under SGID is unlikely. They reported no formation of BCM7 
following 10-60 min digestion with pepsin at pH 2.0. β-casein degradation was monitored 
using LC-MS and the proteolysis seemed to be determined mainly by the amino acid 
sequence of β-casein. 
Using LC-MS/MS, De Noni (2008) investigated the release of BCM5 and BCM7 during 
SGID of bovine β-casein variants (A1, A2 and B) using pepsin digestion at pH 2.0, 3.0 and 4.0 
followed by hydrolysis with Corolase PPTM. β-CN variants were extracted from unprocessed 
milks and digested after dispersion in bovine milk UF permeate. BCM7 was not released 
during initial peptic digestion of any of the β-CN variants studied. Regardless of the pH value, 
B variants of β-casein released during SGID the highest amount of BCM7 (5–176 mmol/mol 
casein), followed by the A1 variant. BCM7 was not released from variant A2 during any steps 
of SGID process. Furthermore, BCM5 was not formed in hydrolysates irrespective of the 
genetic variant of the original β-casein or the pH value employed during SGID. 
The study of Cieslinska et al. (2007) reported the release of BCM7 from a homozygous A2 
milk following digestion (24 h at pH 2.0) with pepsin. Recognition/quantification of BCM7 
was done by means of HPLC/UV and the reported release of BCM7 was four times lower 
from homozygous A2 milk than from homozygous A1 milk. However, the exact levels of 
BCM7 in these milk samples are unknown since the reported data referred to milk extracts 
only. 
Very little information is available on the release of BCMs during digestion of β-casein from 
goat, sheep or buffalo milk. Petrilli et al. (1984) digested β-casein from buffalo milk using 
pepsin, trypsin, chymotrypsin, elastase, carboxypeptidase A, carboxypeptidase B and leucine 
amino peptidase (LAP). The digests were analysed chromatographically by HPLC. Neither 
gastric nor pancreatic enzymes were found to release BCM7. The digests contained a pro-
BCM7 with amino acid sequence corresponding to residues 59-68 of buffalo β-casein. 
However, incubation of this peptide with rabbit small intestinal brush border enzymes did not 
release BCM7. Petrilli et al. (1987) investigated the degradation of a β-casomorphin-
containing fragment (tryptic peptide corresponding to residues 49-68 of buffalo β-casein) 
using pig pancreatic juice. Using fast atom bombardment MS to identify the fragments 
produced, it was reported that incubation with pancreatic juice was not capable of releasing β-
casomorphin or morphiceptin from the tryptic peptide.  
Recently, De Noni (2008) did not find BCM5 or BCM7 in the peptic (pH 2.0 or 3.5) digests 
of milk-based infant formulas following SGID. These products contained both A1 and A2 
 Review of the potential health impact of β-casomorphins and related peptides 
 
 
EFSA Scientific Report (2009) 231, 32-107 
 
variants of β-casein and it was only upon further digestion with Corolase PPTM that BCM7 
levels ranging from 0.02 to 0.37 nmol/mL were detectable. 
BCM7 was recovered but not quantified in the UF permeate of a reconstituted infant formula 
subjected to peptic hydrolysis at pH 3.5 followed by digestion with Corolase PPTM 
(Hernandez-Ledesma et al. 2004). In another study, the same authors did not find the presence 
of this peptide in an infant formula digested with pepsin (pH 3.5) and porcine pancreatin 
(Hernandez-Ledesma et al., 2007). However, the peptide (Val59)-BCM9 was recovered in the 
same infant formula. Using HPLC separation and UV detection, Jarmolowska et al. (2007b) 
reported the presence of BCM5 in peptide extracts of an infant formula and in its pepsin–
trypsin hydrolysate. The amounts of BCM5 in the infant formula extracts and its hydrolysate 
were 0.39 and 43.11 μg/mL (0.67 and 74.46 nmol/mL), respectively. No BCM7 was found in 
the extracts either prior to or after SGID.  
3.2.2 Non-milk derived opioids released in SGID 
Dietary opioid peptides are present in a variety of protein sources, such as wheat, barley, soy, 
spinach (rubisco protein) and blood (Table 2). Fukudome and Yoshikawa (1992) found gluten 
exorphins A5, A4, B4 and B5 in an in vitro digest of wheat gluten with pepsin and 
thermolysin. The same peptides were not released after pepsin digestion alone or in 
pepsin/trypsin/chymotrypsin digests. However, gluten exorphins were found after further 
hydrolysis of the peptic digest with microbial neutral proteinases derived from Aspergillus 
oryzae or Bacillus subtilis. These results suggested that the in vivo release of gluten exorphins 
A and B from wheat gluten might be accomplished by the concerted actions of pepsin and 
enterobacterial proteinases. Fukudome and Yoshikawa (1993) isolated the opioid peptide 
exorphin C from a pepsin-trypsin-chymotrypsin digest of wheat gluten. A subsequent study 
by Fukudome et al. (1997) reported the release of gluten exorphins A and B by the action of 
pepsin and pancreatic elastase. These exorphins could therefore potentially be released in vivo 
by the action of gastrointestinal proteinases following the ingestion of wheat gluten. 
Opioid peptides can also be derived from soy proteins. Agui et al. (2006) reported the release 
of soymorphin-5 after digestion of soy β-conglycinin with pancreatic elastase and LAP. The 
β-subunit of soy β-conglycinin also contains the sequence (YPWT), similar to human BCM4. 
Ohinata et al. (2007) reported the release of human BCM4 and soymorphin-5 during digestion 
of a model peptide corresponding to the β-subunit of soy β-conglycinin with pancreatic 
elastase and LAP.  
Bioactive peptides can be generated in the course of catabolic degradation of technofunctional 
proteins, as reported for hemorphins, a specific group of peptides derived from blood 
haemoglobin. Hemorphins consist of a family of opioid receptor-binding peptides from 4 to 
10 amino acids that are released by proteolytic processing of haemoglobin β-chain (Fruitier-
Arnaudin et al., 2005). The first two haemoglobin-derived peptides identified in vitro and 
termed hemorphin-4 and hemorphin-5 were obtained by incubation of bovine blood with 
gastrointestinal enzymes (Brantl et al., 1986b). These amino acid sequences corresponded to 
the 34-37 and 34-38 fragments of the β-chain of bovine haemoglobin and 35-38 and 35-39 
fragments of the β-chain of human haemoglobin. Two other hemorphins corresponding to 
fragments 31-40 (LVV-hemorphin-7) and 32-40 (VV-hemorphin-7) of the β-chain of bovine 
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haemoglobin have been isolated in vivo from tissues and from fluids. These two opioid 
peptides were also generated during in vitro pepsin digestion of bovine haemoglobin (Garreau 
et al., 1995). Jinsmaa and Yoshikawa (2002) isolated hemorphin-5 from human haemoglobin 
digested with pancreatic elastase. V-hemorphin-5 was also released under the same 
conditions.  
4 POSSIBLE MOLECULAR INTERACTIONS, GENERAL BIOLOGICAL EFFECTS AND FATE 
OF FOOD-DERIVED PEPTIDES  
4.1 Overview 
As has become clear from the previous sections, proteins in food products contain peptides 
which may provoke responses that go beyond typical nutritional or metabolic functions. In 
some of these cases, direct interaction with an enzyme or with one or more receptors may be 
involved. Examples include the inhibition of Angiotensin Converting Enzyme (ACE) or the 
binding to opioid- or other receptors. In other situations, peptides may act in a more indirect 
way, for example via the immune system or by binding of reactive intermediates formed in 
biological processes. This chapter discusses some of the actions and mechanisms that have 
been reported for food-derived peptides, in particular those from milk protein. Some of these 
peptides have been called exomorphins, due to their interaction with opioid receptors. 
Exomorphins can be formed from plant- or animal derived proteins, including milk. It is 
important to note that the fact that these peptides are called exomorphins does not imply that 
their reported effects can always be explained from interactions with opioid receptors. As will 
also become clear from this chapter, particular pharmacological or toxicological mechanisms 
need solid experimental evidence. Moreover, data from in vitro studies or studies performed 
in specific animal models still need to be carefully confirmed by observations in humans, 
since food derived peptides showing activity in vitro might not reach the site of action in the 
organism when administered via the GI tract and results obtained in animal models might not 
be transferable to humans.   
In order to act systemically, peptides should be absorbed from the GI tract into the circulation 
in an active form. This implies that the molecules must first resist hydrolysis by brush border 
peptidases and then be absorbed across the intestinal epithelium. Further degradation can 
occur by peptidases in the liver, in the bloodstream and in other tissues.  A prerequisite to act 
in the CNS is their ability to pass the blood brain barrier (BBB). Peptidases in the brush-
border membrane are actively involved in limiting the absorption of small peptides across the 
intestinal mucosa. Brush-border peptidases are mainly active against tri-, tetra-, and higher 
peptides (up to ten amino acid residues), while intracellular peptidases are active 
predominantly against dipeptides (Pauletti et al., 1996). The amount of peptide which is 
available to pass into the brain depends on the distribution of the peptide within the blood 
compartments and its elimination half-life.  The presence of peptidases and proteinases in the 
blood has been shown to affect the bioavailability of many peptides. These enzymes include 
dipeptidyl(amino) peptidase IV, aminopeptidase A and N, ACE and carboxypeptidase 
(Egleton and Davis, 1997). In order to act in the CNS, (food derived) peptides must cross the 
BBB. The BBB will in principle limit the delivery of peptides to the brain. The endothelial 
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cells that form the BBB are interconnected by tight cellular junctions which provide a high 
transendothelial electrical resistance. Moreover, the BBB acts as a metabolic barrier equipped 
with a number of proteolytic enzymes, such as aminopeptidase A, aminopeptidase M, and 
ACE which are known to degrade peptides (Egleton and Davis, 2005). 
4.2 Interactions of food-derived peptides with opioid receptors  
4.2.1 The opioid system 
Opioid receptors derive their name from the classical effects of the active ingredients of 
opium, in particular morphine and its derivatives. Following the discovery of the first opioid 
receptor in 1973 (Pert and Snyder, 1973; Simon et al., 1973; Terenius, 1973) the first two 
endogenous ligands were quickly identified in bovine brain (Hughes et al., 1975). Since then, 
several other opioid receptor subtypes have been found, as well as a number of endogenous 
and exogenous ligands. Opioid receptors belong to the large family of transmembrane-
spanning G protein-coupled receptors (GPCRs). Different cellular processes can be linked to 
opioid receptor activation, including adenyl cyclase, Ca2+-channels, K+-channels, or 
phospholipase C turnover (Waldhoer et al., 2004). Opioid receptors are most abundant in the 
central nervous system, but can also be found in peripheral nervous, endocrine and immune 
tissues, including the intestinal tract (Wittert et al., 1996; IUPHAR, 2008). Opioid receptors 
are now divided into three different sub-classes. The most current (IUPHAR) recommended 
nomenclature is to denote these as μ (also called MOP), κ (also called KOP) and δ (also called 
DOP). There is also a fourth opioid-like receptor, which is now called N/OFQ 
(nociceptin/orphanin FQ). This receptor is considered ‘opioid-related’ rather than opioid. It 
exhibits a high degree of structural homology with the conventional opioid receptors but 
displays a distinct pharmacology (Alexander et al., 2008) All four receptor groups are about 
65% identical to each other with a common three-dimensional structure that spans the cell 
membrane seven times, forming three extracellular loops and three intracellular loops. The 
seven helical domains have common features defining an opioid-binding pocket and more 
divergent aspects that delineate high affinity and selectivity for receptor sub-type specific 
ligands (Quock et al., 1999). Opioid receptor activation by endogenous and exogenous 
ligands can result in a multitude of effects which include analgesia, respiratory depression, 
euphoria, feeding, the release of hormones, inhibition of gastrointestinal transit, and effects on 
anxiety. In general, agonists selective for μ- and δ-receptors are analgesic and rewarding, 
whereas agonists for κ are dysphoric (Waldhoer et al., 2004).  
Tolerance to opioid ligands is a well-known phenomenon that occurs after chronic exposure 
to such compounds. On theoretical grounds this could become relevant if food-derived opioid 
peptides would be present in significant amounts at the receptor binding site during prolonged 
periods. However, such phenomena have never been described in relation to food-derived 
opioid peptides. Surprisingly, the mechanism (or mechanisms) underlying the development of 
for example morphine tolerance has not been completely elucidated (Waldhoer et al., 2004; 
Bailey et al., 2006; Christie, 2008). Available data suggest that it is unlikely that receptor 
down regulation is solely responsible for the development of morphine tolerance. Other 
processes, including desensitization or uncoupling are probably also involved. 
 Review of the potential health impact of β-casomorphins and related peptides 
 
 
EFSA Scientific Report (2009) 231, 35-107 
 
4.2.2 Endogenous opioids 
Several endogenous ligands for opioid receptors have been discovered. So far, all of these 
were found to possess a peptide structure. The endogenous ligands are often divided into three 
groups: endorphins, enkephalins, and dynorphins (Waldhoer et al., 2004; Foord et al., 2005; 
Fichna et al., 2007; IUPHAR, 2008). Many endogenous opioid peptides are derived from 
inactive precursor polypeptides, including proopiomelanocortin, proenkephalin, and 
prodynorphin, respectively (Waldhoer et al., 2004). Several endogenous ligands contain a 
similar pentapeptide sequence Tyr-Gly-Gly-Phe-Met/Leu (YGGFM/L). Nociceptin/orphanin 
FQ, however, contains a phenylalanine (F) instead of the N-terminal tyrosine. Endomorphin-1 
(Tyr-Pro-Trp-Phe-NH2) and endomorphin-2 (Tyr-Pro-Phe-Phe-NH2) are two endogenous 
tetrapeptides with high affinity and remarkable selectivity for the μ-opioid receptor. See 
Waldhoer et al. (2004) and Balázs (2007) for recent reviews. Other peptides also show some 
selectivity. Enkephalins act in particular on δ-receptors, dynorphins on κ-receptors, but β-
endorphin act both on μ- and δ-receptors with low to moderate affinity only. Endogenous 
opioid peptides function as inhibitory neurotransmitters and neurohormones. They are 
released from nerve cells to act on other cells that bear opioid receptors and thus dampen the 
activity of those cells. They can all modulate the intensity of pain despite the fact that they act 
through different classes of opiate receptors. Opioids are also involved in complex 
behaviours, such as sexual attraction, aggressive/submissive behaviours and eating behaviour. 
They have also been implicated in psychiatric disorders, such as schizophrenia and autism, 
although the evidence for this is debated. Endomorphins have been detected in significant 
levels in immune cells and there is persuasive evidence emerging that they can also exert 
potent anti-inflammatory effects in both acute and chronic peripheral inflammation (Jessop, 
2006). 
4.2.3 Exogenous opioids 
Following the discovery of the medicinal compound morphine several compounds have 
subsequently been synthesized for medical use. These include very potent drugs like fentanyl, 
methadone and pentazocine. Among the medically used opioids, there are, so far, no peptides 
or related compounds. However, it has already been known for almost 30 years that several 
proteins present in our diet contain sequences that, after being released, can at least 
theoretically interact with opioid receptors. The discovery of such exogenous opioid ligands 
was first reported around 1979 (Zioudrou et al., 1979). Since then, several food-derived 
opioid peptides have been described (see Chapter 2.2). The first pharmacological descriptions 
of milk-derived peptides that where later called β-casomorphins date back to the late 1970’s 
(Brantl et al., 1979; Zioudrou et al., 1979; Brantl et al., 1981; Brantl et al., 1982; Koch et al., 
1985). Using standard pharmacological bioassays, including the guinea-pig ileum longitudinal 
muscle myenteric plexus preparation (GPI) and the mouse vas deferens (MVD) as well as 
ligand-binding assays, it was concluded that both bovine and human BCMs predominantly 
bind to the μ-type receptor.  In addition, there seems to be some affinity for the δ-receptors, in 
particular of human BCM4 and BCM5 (Koch et al., 1985). In the GPI assay, human BCMs 
(Tyr-Pro-Phe-Val-Glu-Pro-Ile) were found to be 3 to 30 times less potent than the bovine 
BCMs (Tyr-Pro-Phe-Pro-Gly-Pro-Ile) and 300-600 times less potent than normorphin (Koch 
et al., 1985). The rank order of potencies for human β-casomorphins was the same as for the 
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bovine β-casomorphins (BCM5 > BCM4 > BCM8 > BCM7).  Brantl et al. (1981) estimated 
that the affinities of the (bovine) β-casomorphins for opiate receptors from rat brain, as 
indicated by their IC50 values, where a factor > 300 lower than that of morphine. BCM5 was 
found to be the most potent and BCM7 the least potent.  
Compared to milk-derived opioid peptides, the pharmacology of dietary exorphins from other 
food sources has been studied less well. However, quite a few examples exist. Oryzatensin, a 
peptide from rice albumin, was shown to possess ileum contracting and immunomodulatory 
activities (Takahashi et al. 1994) along with C3a agonist activity leading to anti-analgesic and 
anti-amnesic effects after intra-cerebro-ventricular (i.c.v.) administration (Jinsmaa et al. 2001, 
Takahashi et al. 1996). Rubiscolin-6 is a peptide formed from the enzyme Rubisco, widely 
present in green leaves. It was shown to have analgesic activity (Yang et al. 2001), to exert 
stimulated memory consolidation (Yang et al. 2003) and to have anxiolytic activities in the 
elevated plus maze test in mice (Hirata et al. 2007). Various blood proteins, including 
albumin and γ-globulins (Zioudrou et al. 1979), and haemoglobin (Brantl et al. 1986) can 
release peptides that act as opioid receptor ligands. Peptides from human haemoglobin β-
chain have been related to many in vivo  physiological effects (coronaro-constrictory, anti-
tumor, immunoregulatory activities) and several of the hemorphins interact at various levels 
of the renin-angiotensin system (RAS) by inhibiting ACE, aminopeptidase N and dipeptidyl 
peptidase IV activities (Fruitier-Arnaudin  et al., 2005). In addition, some hemorphins and in 
particular LVV-Hemorphin-7 (LVVYPWTQRF), binds with high affinity to the brain 
(IC50 = 4.15nm) and renal AT4 angiotensin receptor subtype and is possibly the main 
endogenous ligand from this receptor. A peptide with opioid activity can also be formed from 
egg albumin (Zioudrou et al. 1979). Other studies concerned the presence of opioid peptides 
in enzymatic digests of wheat gluten. Zioudrou et al. (1979) found opioid activity in the 
peptic digest of wheat gluten. This activity related to both the inhibition of the contraction of 
the electrically stimulated mouse vas deferens and the inhibition of adenylate cyclase of 
neuroblastoma X-glioma hybrid cells. Gluten exorphin B5 has been shown to stimulate 
prolactin secretion in rat (Fanciulli et al. 2005). Gliadin peptides were shown to block 
leucocytes migration which was inhibited in the presence of naloxone (Graf et al. 1987). 
Takahashi et al. (2000) studied the effects of gluten exorphin A5 on the pain-inhibitory 
system, emotionality and learning/memory processes in ddY mice. Thus, exorphin A5 has 
been found to produce various effects in both the peripheral and central nervous system. 
According to Sun and Cade (2003), following administration, gliadorphin-7 gains access to 
brain cells of normal rats by diffusion through circumventricular organs. A sequence identical 
to human BCM4 (Tyr-Pro-Phe-Val) can be released from the β-conglycinin fraction of soy. 
Recently, Ohinata et al. (2007) described the actions of what they call soymorphins-4,-5,-6 
and -7.  Soymorphins were tested by the GPI and MVD assay, as well as in vivo in mice. They 
were found to be more potent than human BCMs and showed anxiolytic activity (in the 
elevated plus-maze test) after oral administration. The authors also simulated enzymatic 
conditions in which these soymorphins could be formed in the GI tract. In contrast to β-
casomorphins (human and bovine), hemorphin and “soymorphins’, which show μ-receptor 
preference, gluten exorphins and rubiscolin are reported to be more δ-receptor specific.  
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4.3 Non opioid receptor-mediated action of milk-derived peptides 
4.3.1 Milk protein-derived immunomodulatory peptides 
It has been demonstrated that κ-casein and its caseinomacropeptide 106-169 fragment inhibit 
both the mitogen-induced Peyer’s patch B lymphocytes’ proliferation in vitro in mice and 
rabbits. It also inhibits the antibody response induced by sheep red blood cells on mice 
splenocytes (Otani et al., 1992, 1995a,b,c). In addition, αs1-casein, β-casein and κ-casein 
hydrolysates inhibit in vitro B mitogen (LPS, pokeweed mitogen) or T mitogen (PHA, ConA) 
induced splenocytes and Peyer’s patch lymphocyte proliferation (Otani et al., 1993, 1995 a, b, 
c, 1996).  A group of casein-derived peptides modulate the activity of macrophages, that is B 
and T lymphocytes (Parker et al., 1984; Berthou et al., 1987; Migliore Samour and Jollès, 
1988; Kayser and Meisel, 1996). β-casomorphins may also affect the human mucosal immune 
system, possibly via opiate receptors in lamina propria lymphocytes (Elitsur et al., 1991). 
Two peptides isolated from human β-casein, the hexapeptide 54-59 (Val-Gly-Pro-Ile-Pro-Tyr) 
and the 60-62 tripeptide (Gly-Leu-Phe), were found to stimulate the in vitro phagocytic 
activity of sheep red blood cells by murine peritoneal macrophages. In vivo they prevented an 
infection of mice following intravenous injection of bacteria (Klebsiella pneumoniae). In 
addition, the opioid peptide isolated from β-casein (residues 63-68) has been shown to 
stimulate the immune system and particularly phagocytosis. Isracidin, the 1-23 N-terminal 
fragment from αs1-casein B protects mice against infection by Staphylococcus aureus and 
Candida albicans by stimulating phagocytosis and immune response (Lahov and Regelson, 
1996). In addition, α-lactalbumin and derived peptides could modulate intestinal cell 
proliferation and maturation (Alston-Mills et al., 1997). An antimutagenic activity has also 
been observed in whey protein hydrolysates fermented by LAB (Ganjam et al., 1997; Matar et 
al., 1997). Furthermore, immunoactive peptides have been produced from α-lactalbumin and 
lactoferrin. The mechanism by which these peptides exert their immunomodulatory effect has 
not yet been defined but it may be related to their binding/interaction with opiate receptors.  
4.3.2 Other activities of food-derived opioid peptides 
A link between hydrolysed casein formulas, BCM7 and α-casein with pseudo-allergic skin 
reactions in children has been suggested (Kurek et al., 1995; Kurek and Malaczynska, 1999). 
This observation was based on results from skin prick tests. The skin reactions could be 
prevented by pretreatment with antihistaminic drugs. In later studies with isolated rat mast 
cells, α-casein was found to develop a stronger effect than BCM7. The stimulation of opioid 
receptors (in particular of the μ-type) has been shown to cause pruritus and other sensitivity 
reactions which can be blocked by anti-histaminics (Ganesh and Maxwell, 2007; Woodall et 
al., 2008). However, the reports by Kurek may also be related to non-specific mechanisms 
and do not seem to indicate a specific effect of BCMs.  
Ingestion of milk protein components has been linked to tissue development (Britton and 
Kastin, 1991). For instance, casein-derived peptides have been shown to stimulate mitosis of 
different cell types (Azuma et al., 1989; Nagaune et al., 1989; Coste et al., 1992) or to affect 
protein synthesis, proteolysis and ureogenesis (Takenaka et al., 1991). This seems particularly 
important for immunocompetent cells since milk contains components which can modulate 
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the non-specific or specific immune systems. Moreover, it has been suggested that milk 
proteins may be involved in the induction of the autoimmune response in Type-1 or insulin-
dependent diabetes (IDDM). This will be discussed in Chapter 4.5.4. 
There have been some studies on interactions of casomorphins with receptors other than 
opioids. For example, Rüthrich et al. (1993) suggested that there may be an interaction with 
dopaminergic regulation systems. This was based on the effects of BCMs on apomorphine-
induced hyperlocomotion in rats. However, there are no recent studies to confirm this 
hypothesis. Recently, one research group has suggested a possible interaction of BCM7 with 
serotonin systems (Sokolov et al., 2005, 2006, 2008). 
4.4 Absorption and fate of peptides 
4.4.1 Factors affecting absorption of opioid peptides from the GI tract 
The composition of the intestinal content, including food, is subject to significant variation. 
Gastric emptying and intestinal transit can significantly modify the time that a peptide is 
present at a site along the GI tract thereby impacting absorption. In addition, and depending 
on the pKa of the peptide, the pH microclimate could inhibit or favor peptide transport.  
In healthy adults the absorption of peptides larger than di-tripeptides is usually highly 
restricted. In specific situations, such as during stress, certain diseases or aggression, both 
animals and humans display increased intestinal permeability. In the human neonate, the 
question as to whether a given peptide can be absorbed is more complex (Vaarala et al. 1998, 
2008). The neonatal gut is known to be relatively permeable to proteins but with increasing 
age the permeability of the intestine to proteins and macromolecules decreases. Neonatal 
permeability of the GI tract for macromolecules and its alteration with time is species-
dependent. In piglets, a model close to the human newborn, the transport capacity decreases 
rapidly within the first days after birth (Pacha et al., 2000). There is a close relation between 
the degree of maturation and absorptive functions of the intestine. The transport of proteins 
plays an important function during early postnatal life as it facilitates the absorption of growth 
factors and immunoglobulins present in maternal milk. This is crucial for ungulates, such as 
piglets or calves that are born nearly agammaglobulinemic. Nevertheless, other mammals 
which are born more or less hypoglobulinemic, such as rat, mouse, or man, also receive IgG 
passively from the maternal milk through absorption in the proximal small intestine. Although 
intestinal absorption may occur in adults, for example during stress situations (Kuge et al., 
2006) this group is less vulnerable and generally already exposed to a much greater diversity 
of peptides and proteins. 
4.4.2 Transfer mechanisms across the intestinal epithelium 
There are two distinct pathways for peptides to cross the intestinal epithelium, i.e. the 
transcellular and the paracellular pathway, respectively. When transported transcellularly, 
peptides may be metabolised, they can be subject to carrier mediated transport (uptake, efflux, 
antiport, symport) or they can be transported by transcytosis and/or endocytosis (with or 
without hydrolysis). The translocation of peptides across Peyer’s patches could provide 
another mechanism of transfer (Des Rieux et al., 2006, Foltz et al., 2008). Opioid peptides are 
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reported not to be transported by translocation across cellular membranes, that is a mechanism 
used by cell-penetrating peptides (CPPs) (Patel et al., 2007). The physicochemical properties 
of peptides, such as molecular size, hydrogen bonding, conformation, partition coefficient, 
hydrophilicity, lipophilicity, and electrostatic potential can modify the permeation of peptides. 
Opioid peptides are generally highly hydrophobic. Therefore, their transfer across the 
intestinal epithelium may not occur easily (via diffusion or paracellular pathways enhanced 
depending on their hydrophilicity, Iwan et al., 2008). The potential mechanisms of active 
transfer of opioid peptides across the intestinal epithelium have not been clearly established. 
The PEPT1, H+-coupled transporters, are widely expressed in intestinal epithelium and could 
carry only di- and tri-peptides (Ganapathy et al., 2005). The expression of OATP (Organic 
Anion Transporting Polypeptides) is widespread (intestine, brain notably) and three synthetic 
opioids have been shown to be carried by this type of transporter. A new Na+-dependent 
active transport (ARPE-19) has been found in a cell line of epithelial retinal pigment (RPE).  
This transport system accepts a variety of opioid peptides containing 4 to 13 amino acids, the 
distribution pattern of this transport system in tissues other than RPE in mammals is still 
unknown (Hu et al., 2003). Regardless of the barriers and the potential transport mechanisms 
described here it has been recognized that the intestinal mucosa does not present an absolute 
barrier that totally prevents peptide permeation. Various examples of biologically active 
peptides, including fragment of αs1-casein (residues 1-23, Chabance et al., 1998) hexarelin 
(Roumi et al., 2001), pentapeptide from β-casein (HLPLP, Quiros et al., 2008), tetrapeptide 
(GGYR, Shimizu et al., 1997) octreotide (synthetic octapeptide analog of somatostatin, 
Dorkoosh et al., 2004) have been reported to cross the intestinal epithelium (using in vitro or 
in vivo models). Nevertheless, in all reports to date, peptides and peptidomimetics typically 
appear to show poor and variable oral bioavailability (Pauletti et al., 1996). 
4.4.3 Absorption of opioid peptides  
The estimation of peptide bioavailability in humans is generally based on in vitro systems or 
in vivo animal models. In vitro models which are frequently used to screen for intestinal 
absorption include monolayers of the human intestinal cell line Caco-2 and freshly excised rat 
(or other species) intestinal mucosa mounted in Ussing- type chambers. Föger et al. (2008) 
showed that in vitro and in vivo correlations favour the use of Ussing chambers to predict 
bioavailability. The Caco-2 cell line, originally derived from a moderately well-differentiated 
human colon adenocarcinoma (Fogh et al., 1977) was shown to undergo spontaneous in vitro 
enterocytic differentiation (Pinto et al., 1983) leading to the formation of a monolayer of 
highly polarised cells in 2–3 weeks. These cells are joined by functional tight junctions, with 
well-developed and organized microvilli on the apical membrane. Differentiation of Caco-2 
cells results in the polarised expression of brush border hydrolases (i.e. disaccharidases and 
peptidases) and of several transport proteins, normally expressed in the absorptive enterocyte 
of the small intestine (Zweibaum et al., 1991; Hidalgo and Li, 1996). The lack of mucus 
producing goblet cells is one of the major disadvantages of all cell based in vitro models 
(Hilgendorf et al. 2000).  Furthermore a practical problem is that permeability data obtained 
in different laboratories are difficult to compare due to variation in cell line differentiation and 
selection of sub-populations (Hayeshi et al. 2008). 
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The Ussing chambers technique uses intestinal tissue which is mounted between two half-
chambers, establishing a luminal and a serosal side. This allows different compartments of the 
gastro-intestinal tract, from the stomach to the rectum, to be studied at the same time. The 
ability to maintain intestinal tissue alive in a controlled environment has brought scientists to 
use this technique to study the permeability of intestinal tissue to various molecules, including 
ions, nutrients, drugs, small molecule probes and macromolecules (Boudry, 2005) 
Shimizu et al. (1997) demonstrated transepithelial transport of (bovine) BCM5 by human 
intestinal Caco-2 cells. The relative flux of BCM5 increased by treating the layer with an 
inhibitor of dipeptidyl peptidase IV which is implicated in the hydrolysis of the peptide. 
Similar results were found by Iwan et al. (2008) who showed a significant transfer of BCM7 
by Caco-2 cells. The permeability coefficients from apical to basolateral and from basolateral 
to apical side were not significantly different suggesting passive transport across the Caco-2 
monolayer.  
In the study of Singh et al. (1989), the level of BCM7 immunoreactive material (BCMIR) was 
compared in plasma of 2- and 4-week old pups and adult dogs after intake of bovine casein-
based formula, canine milk and soy protein-based formula. Feeding with bovine casein-based 
formula increased BCMIR in plasma in 2- and 4-week old pups but not in adult dogs. BCMIR 
was not found after feeding of soy protein milk. The authors speculated that the intestinal 
mucosa of the newborn is more permeable to the relatively large peptides due to their 
immature tight junction through which peptides cross, thereby escaping hydrolysis. According 
to Singh et al. (1989), the BCMIR is longer than the heptapeptide (BCM7) molecule and 
probably consists of 12-13 amino-acid residues. It is interesting to mention that in this study, 
feeding with canine milk also increased BCMIR in the plasma of pups. In the same study, 
Singh et al. (1989) showed  that BCM7 added to plasma was rapidly degraded whereas the 
BCMIR was stable in plasma.  
Using rabbit ileum mounted in Ussing chambers Mahé et al. (1989a) showed that 
morphiceptin (β-CM4-NH2) was degraded by the intestinal mucosa whereas the β-[DAla2,4, 
Tyr5]-CM5-NH2 peptide resisted hydrolysis and crossed the epithelium intact. The brush-
border peptidases seem to be the limiting step of morphiceptin transfer with dipeptidyl 
peptidase IV enzyme playing a major role. By pre-treatment of the ileum with an inhibitor of 
dipeptidyl peptidase IV the transfer of morphiceptin across this epithelium can be increased. 
Umbach et al. (1985) demonstrated the presence of BCMIR in the plasma of newborn calves 
after milk intake. This BCMIR was not identical to BCM7. Its elution profile during 
chromatography suggested that a considerably larger peptide exists containing the amino acid 
sequence of BCM7. The detected material might represent a precursor of BCM7 which could 
subsequently be released enzymatically at any site in the organism to elicit opioid effects. 
Tomé et al. (1987) showed that BCM5, BCM4 and the analogue β-[DAla2,4, Tyr5]-CM5-
NH2 caused a naloxone-reversible reduction in short-circuit current after addition on the 
serosa side of intestinal mucosa. Only the analogue had an effect after addition on the 
mucosal side. Contrary to the analogue, no intact passage of BCM5 and BCM4 were 
observed. 
Table 7 summarises the results of studies on the absorption of opioid peptides. 
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Table 7. Summary of studies on absorption of opioid peptides 
Peptides/molecules Model Transfer Ref.s 
BCM7 and -5  Caco-2 
Yes 
(Transcellular) 
Iwan et al., 2008 
Shimizu et al., 
1997 
β-CM4-NH2 (morphiceptin) 
 
 
Tyr-D-AIa-Phe-DAIa-Tyr-NH2 
Ussing 
Chambers 
No 
(yes with inhibitor of 
DPP IV) 
Yes 
Mahé et al., 1989a 
Casein-based formula In vivo  (dog pup plasma) 
Yes  
(BCM7 immunoreactive 
material) 
Singh et al., 1989 
unmodified β-CMs 
 
β-[D-Ala2,4,Tyr5]CM-5-NH2 
Ussing 
Chambers 
 
No 
 
Yes  
(Transepithelial 
transfer) 
Tomé et al,. 1987 
Milk intake 
In vivo  (New 
Born calves) 
 
Yes   
β-CM immunoreactive 
material precursor) 
Umbach et al., 
1985 
 
4.4.4 Transport in the blood stream 
The issue of peptide transport in the circulation is complex. Blood contains substantial 
activities of peptidase enzymes. The half-life of certain peptides in plasma is very short, with 
an order of magnitude of one minute (Gardner, 1998). Angiotensin II degradation occurs even 
within seconds (Moskowitz, 2002, 2003). Nevertheless, peptides can also be more resistant to 
hydrolysis in blood, because they may be weakly bound to carrier proteins which can protect 
them. Noncovalent association with albumin has also been shown to extend the half-life of 
short lived proteins (Dennis et al., 2002). Transferrin (Tf), an iron-transporting glycoprotein, 
also appears to be an appropriate candidate as a peptide carrier utilizing transcellular transport 
due to the high expression of the Tf receptor on both the brain endothelium and 
gastrointestinal epithelium (Tuma et al., 2003). However, although its half-life is extended, a 
peptide associated with plasma protein is usually unavailable for binding to the target. To our 
knowledge, in vivo half-lives of BCMs in blood have not been measured. 
4.4.5 Transfer across the blood-brain barrier (BBB) 
The BBB is a physical and metabolic barrier separating the microenvironment of the central 
nervous system (CNS) from the peripheral circulation. It is located at the level of cerebral 
microvessel endothelial cells, which possess morphological and enzymatic properties distinct 
from those of capillaries from other body sections. Some regions of the CNS do not express 
the classical BBB capillary endothelial cells, but have microvessels similar to those of the 
periphery. These areas are adjacent to the ventricles of the brain and are termed the 
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circumventricular organs (CVOs). CVOs are involved in neurohormonal secretion and 
monitoring of blood composition, in these regions the capillaries are more permeable to 
solutes (Egleton and Davis, 1997). 
Four different Peptide Transport Systems have been described for the transfer of peptides 
across the BBB. They are referred to as PTS-1, PTS-2, PTS-3 and PTS-4. (Ganapathy et al., 
2005). Among these 4, only PTS-1 recognizes opioid peptides. The substrates of PTS-1 
include Tyr-MIF-1, Met-enkephalin, Leu-enkephalin, BCM7, and dynorphin 1-8. (Ganapathy 
et al., 2005). Turner et al. (1998) have shown that dynorphin 1-13 can cross the BBB in 
normal cat hippocampus, cortex and cerebellum tissue. 
In conclusion, the hypothesis that an opioid peptide, present and available in the blood can 
cross the BBB, seems possible.  
4.5 Organ and system-specific action of food-derived peptides 
Food-derived peptides, depending on their absorption from the GI tract and their subsequent 
distribution in the body, can potentially act on different tissues and organs. However, the 
majority of studies to date are related to their possible effects on the gastrointestinal tract, the 
CNS and the cardiovascular system. Furthermore, the potential connection with an increased 
risk of developing IDDM has received considerable attention in the scientific literature. These 
topics will be addressed in this chapter. 
4.5.1 Effects of food-derived peptides on gastrointestinal function 
Dietary proteins are known to have regulatory effects on digestive and metabolic processes. 
They modulate mucosal processes and the release of gastro-intestinal hormones, such as 
gastrin, cholecystokinin,secretin and gastrin inhibitory peptide with a subsequent regulatory 
effect on gastro-intestinal motility and on gastric and pancreatic secretions (Hara et al., 1992). 
These effects are partly mediated by amino acids present in the intestinal lumen and in the 
intestinal mucosa after their absorption. They could also be associated with the release of 
specific food protein-derived peptides during digestion which act either on the luminal part of 
the intestinal mucosa or on other targets after their absorption (Daniel et al., 1990). Casein has 
been demonstrated to efficiently stimulate intestinal secretion, thus suggesting the presence 
both in animals and in humans of specific casein-derived peptides acting on gastro-intestinal 
processes (Daniel et al., 1990; Yvon et al., 1994; Mahé et al., 1995, 1996). 
Caseinomacropeptide, the κ-casein-derived fragment, has been proposed as one of these 
casein-derived bioactive peptides (Yvon et al., 1994; Beucher et al., 1994; Perdersen et al., 
2000). Food-derived peptides, including casomorphins can also have different effects in the 
intestinal lumen and the intestinal mucosa. More specifically, BCMs can interact with 
endogenous opioid systems in the gastrointestinal wall in neonates as well as in adults. 
Milk proteins and their peptides have been suggested to have an effect on the gastrointestinal 
ecosystem (Baldi et al., 2005). For instance, casocidin I, the 165-203 fragment released from 
αS2-casein by chymosin, inhibits the growth of Escherichia coli and Staphylococcus carnosus 
(Zucht et al., 1995). β-casomorphins were also shown to modulate intestinal transport of 
amino acids (Brandsch et al., 1994). β-casomorphin fragments were also demonstrated to 
modulate mucus secretion by intestinal mucus producing cells (Claustre et al., 2002; 
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Trompette et al., 2003; Zoghbi et al., 2006). Orally administered milk protein-derived opioid 
peptides have been demonstrated to influence postprandial metabolism by stimulating 
pancreatic polypeptide, insulin and somatostatin secretion (Morley et al., 1983; Schusdziarra 
et al., 1983a,b;  Takahashi et al., 1997; Froetschel, 1996). They have also been suggested to 
attenuate the suppression of fat intake via enterostatin (White et al., 2000). Furthermore, 
BCMs have been demonstrated to prolong gastrointestinal transit time (Daniel et al., 1990; 
Becker et al., 1990; Defilippi et al., 1995; Mihatsch et al., 2005). β-casomorphins could also 
modulate water and electrolyte absorption and exert an anti-diarrheal action in animals and in 
humans (Daniel et al. 1990).  Evidence has accumulated that the enhancement of net water 
and electrolyte absorption by BCMs in the small intestine is a major component of their anti-
diarrheal action which could be mediated via sub-epithelial opioid receptors or through 
specific luminal binding sites at the brush border membrane (Tomé et al., 1987, 1988; 
Mansour et al., 1988; Mahé et al. 1989b).   
4.5.2 Effects of food-derived peptides on the central nervous system  
4.5.2.1 Opioid receptors in the CNS 
Opioid receptors are widely distributed in the brain and are also found in spinal cord and 
peripheral sensory and autonomous nerves (Wittert et al., 1996; Peckys and Landwehrmeyer, 
1999; IUPHAR, 2008). Within the CNS, opioid receptors are involved in several, and rather 
diverse, effects and actions. These include analgesia, sedation, euphoria, dysphoria, appetite 
and eating behaviour, respiratory depression, cough reflexes, nausea and vomiting, and 
pupillary constriction. The μ-receptor, to which BCMs have been reported to bind 
preferentially (Brantl et al., 1981; Brantl et al., 1982;  Koch et al., 1985) shows high 
expression levels in the thalamus, caudate putamen, neocortex, nucleus accumbens, amygdala, 
interpeduncular complex, and inferior and superior colliculi (IUPHAR, 2008). The μ 
receptors are also present in the superficial layers of the dorsal horn of the spinal cord. A 
moderate density of μ receptors is found in periaqueductal gray and raphé nuclei. These brain 
regions have a well-established role in pain and analgesia. Morphine and other opiate 
analgesics, such as fentanyl belong to the most well-known agonists of the μ-receptors. Other 
physiological functions regulated by μ receptors include respiratory and cardiovascular 
functions, intestinal transit, feeding, mood, thermoregulation, hormone secretion and immune 
functions.  
4.5.2.2 Actions of food – derived peptides on CNS functions: data from animal studies  
There are quite a few studies on CNS effects of BCMs obtained in experimental animals. 
Except for the study with the related “soymorphins” (Ohinata et al., 2007), the compounds 
were administered parenterally in all studies reported in the literature.  Brantl et al. (1981) and 
Grecksch et al. (1981)  were the first to report on analgesic activities of BCMs after intra-
cerebro-ventricular (i.c.v.) injection to rats. They found that all four β-casomorphins studied 
(BCM4,-5,-7 and -8) elicited analgesia which could be completely antagonized by naloxone. 
Compared to other BCMs, BCM7 showed the slowest onset of action, but its effect also lasted 
for the longest period (90 min). The authors specifically remarked on the long duration of 
action which was much longer than that of endogenous peptides (for example enkephalins) 
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they had tested. Following these initial reports, several studies have confirmed CNS related 
effects of BCMs after parenteral administration to animals. A summary is given in Table 8.  
Table 8. CNS related effects of β-casomorphins after parenteral administration to animals 
Compounds Animal 
model  
Route of 
administration 
Effect Reference  
BCM4,5,7,8 Rat i.c.v. Analgesic activity which was antagonised by 
naloxone 
Brantl et  al., 
1981 
BCM5 Rat i.c.v. Dose-dependent analgesic activity in two 
different tests, antagonised by naltrexone  
Grecksch et 
al., 1981 
BCM4,5,7 Young 
Chickens 
i.c.v. BCMs reduced separation induced distress 
vocalisations (DVs). BCM5 was more potent 
than either BCM4 or BCM7, with BCM7 having a 
somewhat longer effect. Effects were partially 
antagonised by naloxone 
Panksepp et 
al., 1984 
BCM5 and semi-
synthetic 
derivatives 
Rat i.c.v. and i.v Analgesis, BCM5 > 20 times less potent than 
morphine after i.c.v administration 
Matthies et 
al., 1984 
BCM7 Rat (pups) i.p. (1–100 
mg/kg) 
BCM7 had no effect on waking. At 100 mg/kg 
signs of sleep changes. No signs of respiratory 
depression.  Naloxone pretreatment (1 mg/kg IP) 
reversed the effects of BCM7 on sleep. 
Taira et al., 
1990 
BCM7 Rat i.p.  (1 and 5 
mg/kg) 
 
Accelaration of learning of a food-procuring habit 
in a T-maze. Delayed learning of active 
avoidance response involving the use of a 
painful reinforcing stimulus 
Maklakova 
et al., 1995 
BCM4,5,7 Rat  i.c.v. Only BCM7 stimulated food intake of high fat 
meal. Antagonised by enterostatin and naloxone.  
Lin et al., 
1998 
BCM5 Mouse and 
Neuroblasto
ma cells  
i.c.v. and i.p. BCM5 (i.c.v.) dose- dependently induced 
amnesia  in mice .I.p administration of BCM5  
(0.1–20 mg/kg) had no significant effect on either 
spontaneous alternation behavior or passive 
avoidance response. However, from a series of 
combination studies it was concluded that i.p. of 
a low dose (1 mg/kg) of BCM5 improves the 
disturbance of learning and memory resulting 
from cholinergic dysfunction through central 
mediation involving μ1-opioid receptors.  
β -casomorphins, including BCM7 were found to 
stimulate neurite outgrowth on neuroblastoma 
cells. 
Sakaguchi 
et al., 
2003a; 
Sakaguchi 
et al., 2003 
b; 
Sakaguchi 
et al., 2006 
BCM7, rubiscolin-
5 and exorphin C 
Rat (pups) i.p. Postnatal learning. The three exomorphins 
improved the development of the conditioned 
foraging reflex in a complex maze. Only BCM7 
had an effect (negative) on passive avoidance 
conditioning. Investigators’  conclusion: 
exorphins, in particular β-casomorphins, can 
have significant and long-term effects on the 
environmental adaptation of young mammals. 
Dubynin et 
al., 2008 
BCM7 
 
Rat 
(newborn) 
i.p.  Ex-vivo activation (DNA synthesis) of 
proliferative processes in the myocardium and 
ectodermal and endodermal epithelium of 
newborn rats.  
Maslennikova 
et al., 2008 
Soymorphins-5 
(Tyr-Pro-Phe-Val-
Val), -6 (Tyr-Pro-
Phe-Val-Val-Asn) 
and -7 (Tyr-Pro-
Phe-Val-Val-Asn-
Ala) 
Mouse  Oral  Anxiolytic activities after oral administration at 
doses of 10-30 mg/kg in the elevated plus-maze 
test in mice. Soymorphins were found to be more 
potent than human BCMs. 
Ohinata et 
al., 2007 
i.c.v. = intra-cerebro-ventricular ; i.p. = intra-peritoneal 
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4.5.2.3 Possible links of β-casomorphins with CNS-associated disorders or diseases in 
humans 
Given the possible link between BCMs and CNS-associated disorders, much attention has 
been given to autism and to a lesser extent to the issue of ventilation disorders and sudden 
infant death syndrome (SIDS). 
4.5.2.4 Ventilation disorders, sudden infant death, sleep (and sleep apnea) 
The respiratory depressing activity of opioids in general is well-known. In the clinical setting, 
respiratory depression may limit the use of opioid analgesia. The fundamental drive for 
respiration is generated in the brainstem and is modulated by factors that include conscious 
inputs from the cortex, central (brainstem), and peripheral (carotid and aortic bodies) 
chemoreceptors that sense changes in the chemical constituents of blood (Pattinson, 2008). 
Opioids depress respiration by a number of mechanisms and neuronal sites of action, and 
differences between various opioids exist, even within a specific class (e.g. μ-receptor binding 
compounds). There are also links between opioid use, sleep apnea and sleep disturbances in 
general (Wang and Teichtahl, 2007). Opioid receptors are located in the same nuclei that are 
active in sleep regulation and opioid peptides are suggested to be involved in the induction 
and maintenance of the sleep state. Abnormal sleep architecture has been reported during the 
process of opioid induction, maintenance and withdrawal. During induction and maintenance 
of opioid use there is a reduction of rapid eye movement (REM) sleep and slow wave sleep. 
More recently, central sleep apnea (CSA) has been reported with chronic opioid use and 30% 
of stable methadone maintenance treatment patients have CSA. 
The pathogenesis of SIDS is complex and multifactorial. Sun et al. (2003) have reviewed the 
possible relationship between BCMs and SIDS. This review is based on the assumption that 
BCMs might be absorbed from the infant’s GI tract and that they also easily pass through the 
BBB because of the infant’s immature CNS. Based on these assumptions, the authors 
speculate that in infants with abnormal respiratory control and vagal nerve development, 
opioid peptides derived from milk might induce depression of the brain-stem respiratory 
centers, leading to apnea and death. As bovine BCMs might be more potent than their 
analogues in human milk or have different relative receptor preference this might increase the 
risk for SIDS. However, Sun et al. (2003) also mention that infants fed either formula 
preparations or human milk have a similar risk of developing SIDS. 
4.5.2.5 Autism 
Autistic spectrum disorders (ASDs) usually include autism, atypical autism, Asperger’s 
syndrome and some related disorders (Cass et al., 2006) Autism is a complex 
neurodevelopmental disorder characterized by impaired reciprocal social interaction, impaired 
communication, and restricted, repetitive, or stereotyped behaviors (Barbaresi et al., 2006). 
The population of children with autism is very heterogeneous. Autism and related conditions 
in the autism spectrum have become the focus of intense interest which is also stimulated by 
public concerns about the apparent increase in the number of children with these 
developmental disorders. The aetiology of ASDs is still unclear, and medical or psychological 
treatment options often provide disappointing results. Probably also as a result of this, 
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considerable attention is being paid to nutritional, other environmental factors and 
complementary therapies (Barbaresi et al., 2006). 
Among these, the “leaky gut” concept has attracted much attention. This concept is often also 
linked to another hypothetical cause, which is vaccination. For example, there have been 
concerns about the potential role of the measles-mumps-rubella (MMR) vaccine in the 
causation of autism. This theory suggests that the MMR vaccine produces enterocolitis, 
thereby causing or increasing a “leaky gut”.  In the meantime, epidemiologic studies have 
failed to show an association between the MMR vaccine and autism. The “leaky gut” concept 
itself has been fueled in particular by the publication of Cade et al. (2000) which is based on 
the increase of peptide containing peaks in urine samples of autistic and schizophrenic 
patients. However, these peaks have only been partly characterized. Moreover, the dietary 
intervention that apparently led to improvements was both gluten- and casein free. 
Nevertheless, the “leaky gut” concept has received considerable support and has become the 
basis of diets that exclude gluten and casein for ASD patients. Further support has come from 
Reichelt and Knivsberg (2003) who presented an “autism model”, suggesting that exorphins 
and serotonin uptake modulators are key mediators in the development of autism. They 
speculated that this is due to a genetically based peptidase deficiency in at least two or more 
peptidases and/or of peptidase regulating proteins. 
Since then however, this model has been questioned by many authors. In subsequent studies 
using more sensitive and specific LC/MS based analytical methods, the peptides could not be 
detected. Hunter et al. (2003) tried to confirm the presence of opioid peptides in the urine of 
children with autism and to determine whether dipeptidyl peptidase IV is defective in children 
with autism. However, they were not able to detect opioid peptides nor did they find any 
proof for a dipeptidyl peptidase IV deficiency in these children. Recently, Cass et al. (2008) 
using MALDI-TOF MS to analyse opioid-derived peptides concluded that there was no 
evidence for any opioid peptiduria in children with autism. They state that “opioid peptides 
can neither serve as a biomedical marker for autism nor be employed to predict or monitor 
response to a casein- and gluten-free diet”. Christison and Ivany (2006) reviewed the gluten 
and casein elimination diets, concluding that the currently available data are inadequate to 
guide treatment recommendations and that diets eliminating both gluten and casein (rather 
than either alone) should be studied first and that outcome measures should include 
assessments of nonverbal cognition. Dettmer et al. (2007) were also unable to detect 
gliadinomorphin, BCMs, deltorphin 1, or deltorphin 2 in urine of children with ASD. A recent 
Chochrane review (Millward et al., 2008) also concluded that despite the high rates of use of 
complementary and alternative therapies (CAM) for children with autism including gluten 
and/or casein exclusion diets, current evidence for the efficacy of these diets is poor. In 
conclusion, recent data do not provide any support to link intake of casein or peptides derived 
from it to ASD. 
4.5.3 Effect of milk- derived peptides on cardiovascular health 
In relation to cardiovascular health most attention has focused on the antihypertensive 
properties of food-derived peptides. In animal models and human intervention studies, several 
of these peptides, including those that can be formed from milk proteins, have been shown to 
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reduce blood pressure. It was recently demonstrated that the lactotripeptide Ile-Pro-Pro 
selectively escapes intestinal degradation and reaches the circulation undegraded (Foltz et 
al.2007). The properties and clinical effects of antihypertensive milk peptides have been 
reviewed in many recent papers (Korhonen and Pihlanto, 2006; FitzGerald and Meisel, 2007; 
Hartmann and Meisel, 2007; Hong et al., 2008; Möller et al., 2008; Saito, 2008) The most 
important mechanism, at least in vitro, seems to be inhibition of ACE. Although the 
discussion about its relevance and the long-term effects on clinical endpoints continues, the 
reduction in blood pressure by food-derived peptides is generally considered as beneficial. 
4.5.3.1 Oxidation of LDL 
In relation to casomorphins, there have been some suggestions that BCM7 could be pro-
atherogenic (Allison and Clarke, 2006) This effect is supposed to be mediated via stimulation 
of the oxidation of low-density lipoproteins (LDL).  
The LDL fraction is an important lipid carrier in plasma, and consists of cholesteryl ester, 
phospholipids, free cholesterol and triglyceride, and apolipoprotein B100 (ApoB100) (Stocker 
and Keaney, 2004). LDL is derived in the circulation from VLDL. It is essential for the 
transport of cholesterol to peripheral tissues and the regulation of cholesterol metabolism at 
these sites. Like VLDL. LDL contains ApoB100 as apoprotein, a 500 kDa single peptide 
chain synthesised in the liver.  LDL is extremely susceptible to oxidative damage (Steinberg, 
1997; Steinberg, 2002; Stocker and Keaney, 2004; Beck et al., 2008; Matsuura et al., 2008). 
This oxidation is considered as a key factor in the pathogenesis of atherosclerosis and 
cardiovascular disease. Elevated circulating oxidised LDL particles (oxLDLs) are associated 
with more severe atherosclerotic lesions. High circulating levels of oxLDLs have been shown 
to be independently predictive of sub-clinical atherosclerosis and acute coronary heart 
disease. It is assumed that LDL oxidation does not take place in the circulation because of the 
high anti-oxidant activity in plasma. Instead, LDL is supposed to be oxidised in the sub-
endothelial space where it may be exposed to cell-derived free radicals and other reactive 
oxygen- and nitrogen species. The bidirectional transit of LDL across this space may also 
result in a small amount of circulating oxLDL (Stocker and Keaney, 2004). When LDL is 
oxidised, the molecule is recognized by scavenger receptors present on macrophages which 
do not bind native LDL. These macrophages can become lipid laden, transforming to so-
called foam cells. In addition, oxLDL has many other properties that are potentially pro-
atherogenic. For example, oxLDL is itself directly chemotactic for monocytes and T cells 
(Steinberg, 2002). Oxidised LDL is immunogenic (Matsuura et al., 2008). A large number of 
epitopes within the ApoB100 component of oxidised LDL have been identified that provoke 
an immune response (Stocker and Keaney, 2004). As a result, antibodies against oxLDL and 
its complexes may also be markers of cardiovascular diseases. It should be noted that in 
addition to LDL oxidation, other processes, such as inflammation, are important in the 
development of atherosclerosis (Steinberg, 2002). In addition to foam cells, other cell types, 
such as vascular smooth muscle cells and lymphocytes participate in plaque formation 
(Stocker and Keaney, 2004). In LDL oxidation, both the lipids and the apoB100 are oxidised. 
LDL oxidation is stimulated in a lipid-rich environment and probably also after consuming a 
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high fat meal which stimulates oxidative stress conditions (Campbell et al., 2006). 
Furthermore, it is increased by cigarette smoking and with obesity (Beck et al., 2008).  
Several anti-oxidants have been shown to inhibit LDL oxidation (Campbell et al., 2006; 
Lapointe et al., 2006). The in vivo evidence is less consistent, especially with studies using 
flavonoid or vitamin supplements (Lapointe et al., 2006). A healthy food pattern, such as the 
Mediterranean-style diet has been associated with decreased oxidation of LDL, whereas low 
serum carotenoids have been associated with higher ox-LDL (Lapointe et al., 2006; Beck et 
al., 2008).   
Other compounds that may inhibit LDL oxidation include estrogens, melatonin and brain 
monoamines (Lin et al., 2006). Most interestingly, also peptides can act as inhibitors of LDL 
oxidation. Lin et al., (2006) reported that endomorphin-1 and endomorphin-2 may inhibit the 
formation of oxLDL. The anti-oxidant properties of small peptides in general, including those 
of enkephalins have been more extensively studied.  Several peptides possess free radical 
scavenging activities and the capacity to reduce reactive oxygen species (ROS)-induced lipid 
peroxidation (Coccia et al., 2001; Fontana et al., 2001). Food-derived peptides can also act as 
anti-oxidants. This includes peptides from dairy sources, including bovine (Suetsuna et al., 
2000) and ovine (Gómez-Ruiz et al., 2008) casein and bovine whey (Peng et al., 2008). The 
original hypothesis of a pro-oxidant effect of BCM7 dates back to the report of Torreilles and 
Guerin (1995). These authors report the ex-vivo stimulation of LDL oxidation by bovine 
casein hydrolysates with tyrosyl residues. However, Tyr-residues are very common in food-
derived peptides. The findings of Torreilles and Guerin are in contrast to later reports and may 
possibly be due to specific experimental conditions. Apart from the original communication 
proposing a role for BCM7 in LDL oxidation (Torreilles and Guerin, 1995) there are no other 
studies reported to confirm this hypothesis. 
4.5.3.2 Effects of BCM7 in a rabbit model for atherosclerosis   
The publication of Tailford et al. (2003) describing the effects of β-casein A1 versus β-casein 
A2 on atherosclerosis development in a rabbit model for restenosis has received considerable 
attention. In this model endothelial injury is induced using a balloon catheter inserted into the 
carotid artery (Manderson et al., 1989). Following surgery, rabbits were fed for 6 weeks a diet 
containing 0, 5, 10 or 20% casein isolate, either β-casein variant A1 or A2 made up to 20% 
milk protein with whey. Some groups had their diets supplemented with 0.5% cholesterol. 
The authors reported that in the absence of dietary cholesterol, β-casein A1 produced 
significantly higher serum cholesterol, LDL, HDL and triglyceride levels than on a whey diet 
alone which in turn produced higher levels than β-casein A2. Rabbits fed β-casein A1 were 
found to have a higher percent surface area of aorta covered by fatty streaks than those fed β-
casein A2 and the thickness of the fatty streak lesions in the aortic arch was significantly 
higher. From their results, the authors concluded that β-casein A1 was atherogenic whereas β-
casein A2 was not.  However, according to the journal editor, this conclusion can be 
considered as premature (Mann and Skeaff, 2003). In the model used, an acute tissue repair 
process is dominating which is different from the slowly developing atherosclerosis process 
as it occurs in man. Fatty streaks are made up of foam cells which during normal 
atherosclerosis develop from macrophages that have taken up oxLDL. In a damaged vessel 
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wall there may be considerable oxidative stress which induces oxLDL formation. The model 
have also been found to be sensitive to variations in dietary composition in general (Stocker 
and Keaney, 2004) and the rabbit is particularly sensitive to cholesterol. Therefore, small 
differences in dietary composition not related to casein may also have played a role. 
Given the specific limitations of the experimental animal model (rabbit restenosis model) the 
study of Tailford et al. (2003) does not appear to be relevant to support the suggested pro-
atherosclerotic role of BCM7. 
4.5.3.3 Human studies 
The hypothesis suggesting a possible health impact of BCMs and related peptides, in 
particular BCM7, is largely based on ecological studies correlating a few environmental 
factors and the prevalence/incidence of some non-communicable diseases. General 
considerations on human correlational studies and additional considerations on their 
uncertainty are, therefore, appropriate (Morgenstern and Thomas, 1993). The relationship 
between a disease and genetic, behavioural or environmental factors is complex. The 
establishment of a mono-causal theory to explain the prevalence/incidence of a disease is 
therefore problematic. The most appropriate way to confirm a hypothesis is to conduct a 
prospective cohort study at an individual level throughout life, collect complete data on 
genetics, diet, lifestyle and environment and analyse the data on the disease 
prevalence/incidence while adjusting for all other possible influencing factors.  
However, due to the large amount of data which has to be collected and the time such a study 
would take, many other approaches are used. Examples are shorter prospective studies and 
trials with different endpoints as for example risk factors for the disease in question.  For 
many diseases this is extremely hard as risk factors are not known or not measurable.  
Another choice is represented by a case-control study matching to each observed case (person 
with diagnosed disease) a fixed number of controls (persons without the disease). Other 
influencing factors, including sex, age, time point, living region and social status should be as 
much as possible similar between the case and the controls. At the same time the variation in 
the suspected influencing factor should be large enough to observe an effect, which can be 
distinguished from a random variation. However, case-control studies need to assess 
retrospectively the value of the suspected influencing factor, when it is supposed to have 
caused the disease. This can vary for some diseases from the prenatal period and infancy to 
adulthood, therefore some important information may not be available. The same problem 
arises when other influencing factors can be presumed but not assessed. These factors which 
are unknown but which may have an impact on the disease are called “confounders” or 
“confounding factors”. These weaknesses justify the fact that case-control studies are less 
credited to show evidence for an assumed relationship. 
An additional way to test a hypothesis is to conduct an ecological study. This approach has 
intrinsic weakness. Instead of collecting data at individual level, summarised data at group 
level are used and compared. These data are generally easier to access but the implicit 
assumption of homogeneity at individual level is in most cases incompatible with a use of the 
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results of the study to demonstrate a cause – effect association. This can only be a first step to 
gain evidence for a hypothesis. 
The processes leading to major cardiovascular diseases (CVD), such as ischaemic heart 
disease and stroke, are multifactorial and develop usually over a long period before 
diagnosed, most typically, after the age of 50 to 60 years. CVD is considered as a lifestyle 
disease complex and in many countries, in particular in countries with high living standards, 
the prevalence of CVD is high being the major cause of mortality (WHO, 2003). Therefore, 
CVD has been extensively investigated for decades. Many risk factors have been defined and 
some of them develop over a series of years, even from early childhood. These include high 
blood pressure, high LDL cholesterol, low HDL-cholesterol, inflammatory markers, 
homocysteine, smoking, physical inactivity and central obesity. On the other hand, the 
increased prevalence of obesity in young populations has been associated with increased 
prevalence of type 2 diabetes among young people. Type 2 diabetics have an increased risk of 
CVD. Current scientific research associates CVD and type 2 diabetes with inflammatory, 
immunological and metabolic disorders in the organ functions. The fundamental mechanisms 
of these dysfunctions are not fully understood but recent hypotheses implicate chronic 
inflammation as one of the causal factors. The potential role of diet in regulating the initiation 
and development of inflammatory processes in the body has been recently reviewed (Nicklas 
et al. 2005).  
Some ecological studies have linked the intake of β-casein A1 with cardiovascular disease 
mortality. These studies have used an estimated per capita consumption of β-casein A1 from 
dairy foods, based on other studies and statistical reports. The compiled data included for 
example protein content and allele frequency distributions of β-casein in milk of different cow 
breeds in selected countries. The calculated β-casein A1 intake figures were then correlated to 
the CVD prevalence in the same countries. 
An early report hypothesised an association between estimated milk protein intake (not 
including cheese) and deaths from coronary heart disease (Seely, 1981). McLachlan (2001) 
subsequently suggested a strong correlation between the estimated per capita intake of β-
casein A1 (excluding protein from cheese) in 16 countries around 1980 and ischaemic heart 
disease mortality as recorded 5 or 10 years later. In the same study he suggested that “there 
may be an intimate relationship between smoking, the consumption of β-casein A1 and deaths 
from CVD and lung cancer”. 
Laugesen and Elliott (2003a,b) also reported a correlation between the calculated per capita 
consumption of β-casein A1 (excluding protein from cheese and butter) and the prevalence of 
ischaemic heart disease mortality in 20 countries. However, in contrast with the previously 
mentioned study, this latter study could not find a relationship between the consumption of 
tobacco and CVD. This illustrates the fact that ecological studies cannot adjust for all the 
confounding factors. 
Using data from the 1970s, Hill et al. (2002) reported a similar association as the above 
researchers concerning the consumption of β-casein A1 and the prevalence of CVD. However, 
when using data from the 1990s the association was weak. These authors concluded that since 
the relative proportion of β-casein A1 was apparently increasing in milk over this time period 
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in the relevant countries, the consumption of this protein had no effect on ischaemic heart 
disease related mortality (Hill et al. 2002). In contrast to the above studies, more recent large 
cohort studies have suggested a beneficial role for milk consumption in the prevention of 
heart disease and stroke (Elwood et al. 2004a,b, 2005a,b). 
Two human intervention studies have been published about the possible relationship between 
consumption of β-casein A1 or A2 and CVD. Chin-Dusting et al. (2006) performed a double 
blind crossover study in 15 subjects who received 25 g/day of β-casein A1 compared with the 
same dose of β-casein A2 for 12 weeks. No differences were found in any of the endothelial 
and functional tests performed between the two treatments.  Venn et al. (2006) tested whether 
β-casein A1 and A2 variants differentially affected plasma cholesterol concentrations in 
humans. In a randomised crossover trial with 62 subjects of two four-and-a-half week periods 
without washout they found no evidence that dairy products containing β-casein A1 or A2 
exerted differential effects (P > 0.05) on plasma cholesterol concentrations. According to 
these results, β-casein A1 does not seem to be linked to cardiovascular disease. Even though 
randomised intervention studies are considered to provide the strongest body of evidence the 
above studies do not allow firm conclusions to be made, given the limited number of subjects 
and the short intervention periods. 
Therefore, overall, it can be concluded that, to date no definitive scientific data exist that link 
consumption of β-casein variants with increased risk of CVD in humans. 
4.5.4 Food-derived peptides and type 1 diabetes mellitus  
4.5.4.1 Pathogenesis and incidence of type 1 diabetes 
Type 1 diabetes (insulin dependent diabetes mellitus) is an autoimmune disease induced in 
genetically predisposed individuals by environmental factors and results from the progressive 
destruction of insulin secreting pancreatic β-cells by autoreactive T-lymphocytes and 
macrophages, leading to insulin deficiency, probably over a period of months or years 
(Atkinson and Maclaren, 1994; Simone and Eisenbach, 1996; Rabinovitch and Suarez-
Pinzon, 1998; Schranz and Lernmark, 1998). At least half of the patients are diagnosed before 
or around reaching puberty (Atkinson and Eisenbarth, 2001). The development of type 1 
diabetes in genetically susceptible individuals has been divided into a series of steps, 
including its “triggering” by environmental risk factors, the induction of active cellular 
autoimmunity against islet cells often associated with the presence of auto-antibodies and the 
loss of β-cell function and progressive total or near total β-cell destruction with insulin 
dependence. 
Type 1 diabetes is the second most common chronic childhood disease in the world after 
allergy (David et al., 1994). The incidence has been increasing worldwide although there is 
large geographical variation (Akerblom and Knip 1998; Onkamo et al., 1999; Atkinson and 
Eisenbarth 2001; Peter 2007). It has been suggested that the incidence of type 1 diabetes will 
be about 40% higher in 2010 than in 1998 (Onkamo et al., 1999). The increase in recent years 
has been most pronounced in very young children (Tuomilehto et al., 1999; Dahlquist and 
Mustonen 2000; Pozzilli et al., 2007). Incidence figures originate from researchers and 
registers within a country, sometimes collected in review papers (Onkamo et al., 1999), or 
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they are collected by organizations, such as the DIAMOND study of the World Health 
Organization (Karvonen et al., 1993; Karvonen et al., 2000; DIAMOND 2006) or the 
EURODIAB group (Green et al., 1992; EURODIAB 2000). Incidence figures represent the 
whole country or specific regions. The highest incidence is found in Caucasian populations 
and particularly in Northern Europe (Onkamo et al., 1999). Finland is reported to have a very 
high incidence of type 1 diabetes. This may be due to a special genetic susceptibility to type 1 
diabetes and exposure to specific, as yet unknown, environmental factors that trigger the 
disease more efficiently (Tuomilehto-Wolf et al., 1989; Reijonen et al., 1991).  
Type 1 diabetes patients present autoantibodies that recognise insulin secreting pancreatic β-
cell protein autoantigens. These autoantibodies are measured and used to identify subjects at 
risk of developing type 1 diabetes. In 80-90% of patients, autoantibodies can be detected 
against at least one of three islet cell autoantigen (ICA) proteins, including insulin or 
proinsulin, the smaller form of the neuroendocrine enzyme glutamic acid decarboxylase 
(GAD65) and a 40-kDa tryptic fragment of the β-islet cell tyrosine phosphatase (called 
ICA512 or IA-2) (Ziegler et al., 1991; Julier et al., 1991; Hawa et al., 1997). These 
autoantibodies are associated with a high risk (68-90%) for development of the disease (Verge 
et al., 1996; Pietropaolo et al., 1998). Auto-antibodies to other islet cell proteins are less 
frequent and include GAD67 that cross-reacts with GAD65 and possibly ICA69 (also named 
p69), a 69kD β-cell membrane protein which is inducible by interferon gamma and 
carboxypeptidase (Castano, 1991; Pietropaolo et al., 1993; Riechter et al., 1993; Lampasona 
et al., 1994; Martin et al., 1996). Autoantigen-specific T cell clones have also been described 
from patients with type 1 diabetes (Naquet, 1988; Hammer et al., 1993; Atkinson et al., 1994; 
McLaurin et al., 1995; Rammensee et al., 1995; Endl et al., 1996; Wicker et al., 1996; Palmer 
et al., 1997; Verheijden et al., 1997; Geluk et al., 1998; Schloot et al., 1997). Nevertheless, in 
contrast to other autoimmune conditions in which the autoantibodies may be directly 
responsible for disease pathology (Solimena et al., 1990; Blackett et al., 1994; Bhol et al., 
1995; Elkon 2000) the role of autoantibodies in type 1 diabetes is currently not known and in 
no case have autoantibodies been proven to be directly involved either in tissue destruction or 
in disease progression (Hagopian et al., 1993; Kim et al., 1994; Wucherphennig et al., 1995, 
1994; Bach et al., 1997; Patel et al., 1997; Falcone et al., 1998). Studies support the findings 
that T cell proliferative responses to self peptides are not disease-specific (Cosgrove et al., 
1991; Kileen et al., 1993; Fugger et al., 1994; Van der Auwera et al., 1996; Undlien, 1997).  
The finding that a gut-specific adhesion molecule (a4b7-integrin) was expressed in a specific 
population of β-cell-reactive T-lymphocytes was discussed as a link between the gut immune 
system and type 1 diabetes (Paronen et al., 1997). It was hypothesised that dysregulation of 
the gut immune system could result in an unspecific stimulation of recirculating lymphocytes 
which finally react with pancreatic antigens (Akerblom and Vaarala, 1997).  
4.5.4.2 Genetic and environmental factors and involvement of milk in type 1 diabetes 
The genetic origin of type 1 diabetes is clear (Redondo et al., 1999; Zalloua et al., 2002) but 
genetic predisposition alone is not sufficient to cause the disease. The prevalence of type 1 
diabetes in the general population is low (0.5-1%) while 20-30% of the population have 
disease-susceptible human leukocyte antigen (HLA) alleles. 
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The risk of type 1 diabetes is higher in monozygotic twins than in dizygotic twins and first-
degree relatives, but the concordance rate for monozygotic twins is only 30-50% (Kyvik et 
al., 1992; Kaprio et al., 1995). Only 10-15% of all new cases of type 1 diabetes have a close 
family history of the disease (Tuomilehto et al., 1992; Bingley et al., 1993; Atkinson and 
Maclaren, 1994; Dahlquist and Mustonen, 2000). The association between autoimmune 
disease and certain major histo-compatibility complex-HLA class II alleles has been described 
(Svejgaard et al., 1982). The main locus defining the genetic susceptibility to type 1 diabetes 
is encoded within the HLA region on human chromosome 6 (Thomson, 1984; Todd et al., 
1987; Morel et al., 1988; Schrezenmeier et al., 1993; Davies et al., 1994; Todd and Farrall, 
1996; Sanjeevi et al., 1996; She et al., 1996; Buzzetti et al., 1998; Sanjeevi 2000). HLA 
diversity in different populations may have implications for both diabetes prediction and 
incidence. Several non-HLA gene associations have also been identified, such as the insulin 
gene region but their exact role in the risk of type 1 diabetes awaits clarification (Davies et al., 
1994; Buzzetti et al., 1998; Ikegami et al., 2006). Other candidate loci associated with this 
disease have also been proposed on chromosomes 2, 11, and 15 (Field et al., 1994; Hashimoto 
et al., 1994; Owerbach and Gabbay, 1995; Nistico et al., 1996; Larsen et al., 1999; Marron et 
al., 2000). 
The pathologic development of the disease is the result of a combination of genetic and 
environmental risk factors (Elliott, 1989; Atkinson and Maclaren, 1994; Dahlquist, 1994; 
Drash et al., 1994; Akerblom and Knip, 1998; Schrezenmeir and Jagla, 2000). Environmental 
factors have a high impact on disease development (60% to 70%) and the increasing 
incidence and prevalence of diabetes worldwide can only be explained by environmental 
changes (Amos et al., 1997; King et al., 1998). The importance of environmental factors in 
the aetiology of type 1 diabetes is indicated by the observation that the risk that monozygotic 
twins both develop diabetes is low (Kaprio et al., 1992; Kyvik et al., 1995), by its different 
incidences in nations that are genetically close, such as the Nordic countries (Wijsman 1984; 
Backman et al., 1998) and by migration studies showing that the migrant population often 
develops towards a similar incidence to that found in the new country (Bodansky et al., 1992; 
Elliott 1992; David et al., 1994). The possible mechanisms by which environmental risk 
factors trigger type 1 diabetes are classified in three main non exclusive categories. They 
include (1) a direct initial inflammatory disruption of pancreatic islets by "toxic agents"; (2) 
an immunological effect in part ascribed to structural similarities between certain regions of 
foreign proteins and islet cell antigens; (3) an impairment of both the discrimination between 
“foreign” and “own” haptens (Leech 1998) and the gut associated immune system (Vaarala, 
2008).  
Dietary risk factors are important in type 1 diabetes. Some studies have found an association 
between type 1 diabetes and short duration of breast feeding, early introduction of cow’s milk, 
consumption of milk in childhood or per capita milk consumption (Borch-Johnsen et al., 
1984; Mayer et al., 1988; Siemiatycki et al., 1989; Scott 1990; Dahl-Jorgensen et al. 1991; 
Virtanen et al., 1991; Kostraba et al., 1993; Virtanen et al., 1993; Fava et al. 1994; Gerstein 
1994; Virtanen et al., 1994a, b, c; Vaarala et al., 1995; Norris and Scott 1996; Perez-Bravo et 
al., 1996; Gimeno et al., 1997; Virtanen et al., 1998; Schrezenmeir and Jagla, 2000). 
However, such an association is not observed in all the studies (Nigro et al., 1985; Fort et al., 
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1986; Kyvik et al., 1992; Samuelsson et al., 1993; Bodington et al., 1994; Patterson et al., 
1994; Norris et al., 1996; Meloni et al., 1997; Thorsdottir et al., 2000; Zalloua et al., 2002). In 
addition, regions with different levels of milk consumption present similar incidence of 
diabetes (Reunanen et al., 1982; Fava et al., 1994; Muntoni et al., 1997; Elliott et al., 1999; 
Lien et al., 1999; Thorsdottir et al. 2000; Kaminsky, 2007).  
Other dietary risk factors include soy milk formulas, gluten and wheat consumption at young 
age (Scott et al., 1997; Akerblom and Knip 1998; Strotmeyer et al., 2004; Frisk et al., 2008). 
About one out of 20 type 1 diabetics also has coeliac disease (Savilahti et al., 1986; Atkinson 
and Eisenbarth 2001; Hansen et al. 2001; Franzese et al. 2007; Dubois PC and van Heel 2008; 
Frisk et al., 2008). Moreover, solid food intakes resulted in a higher risk in individuals 
genetically predisposed to diabetes (Kostraba et al., 1992, 1993; Perez-Bravo et al., 1996). 
Certain toxic chemicals are also proposed as risk factors. These include N-nitroso derivatives, 
such as streptozotocin (Knip and Akerblom, 1999), a compound toxic to β-cells and 
extensively used in inducing type 1 diabetes in experimental animals (Lampeter et al., 1989). 
A possible role of nitrates has been suggested in both an animal and an observational study 
(Helgason and Jonasson 1981; Helgason et al., 1982). This finding has been supported by 
some epidemiological studies (Virtanen et al., 1994b) while some others do not find an 
association (Muntoni et al., 2006a,b). In contrast, vitamin E (Knekt et al., 1999) and vitamin 
D (EURODIAB 1999; Stene et al., 2000; Hypponen et al., 2001) are considered potential 
preventive factors in humans. Supplementation studies ongoing for several years among 
children at risk for diabetes have investigated the effect of nicotinamide suggesting it to have 
a beneficial effect (Elliott et al., 1996b; Lampeter et al., 1998) although this has later been 
disputed (Hypponen, 2004).  
Other risk factors are also involved in type 1 diabetes. High growth rate has been proposed as 
a risk factor (Blom et al. 1992; Johansson et al., 1994). It has been discussed whether higher 
weight gain in infants fed formula compared to breast milk might explain the relationship 
seen as not being due to the consumption of cow’s milk (protein) per se (Johansson et al., 
1994; Akerblom and Knip, 1998). Accelerated linear growth and increasing body mass has 
been suggested to contribute to the rising incidence of childhood type 1 diabetes. This effect 
might be mediated through increased beta-cell stress induced by hyperinsulinemia and 
decreased insulin sensitivity (Knip et al., 2008). Other proposed risk factors include coffee or 
tea consumption (Virtanen et al., 1994c), physiological stress (Atkinson and Eisenbarth, 
2001), climatic variations (Helgason et al., 1992), exposure to insecticides (Akerblom and 
Knip, 1998), poor sanitation, lack of access to health care and vaccination (Atkinson and 
Eisenbarth, 2001). Lastly viral infections, such as coxsackie B4 virus and the cytomegalovirus 
are probably also involved (Akerblom and Knip, 1998; Dahlquist, 1997). Coxsackie B4 virus 
is one of the viruses most associated with type 1 diabetes and some studies show the presence 
of immune responses to coxsackie virus antigens in type 1 diabetes children and suggest its 
implication with type 1 diabetes autoimmunity. This may be either by direct inflammatory 
disruption of islets or induction of an immune response (Juhela et al., 2000; Serreze et al., 
2000; Jaïdane and Hober, 2008). In contrast, a reduced risk has been associated with multiple 
infections during the first few years of life, while an increased risk has been associated with 
perinatal infections. A protective effect of preschool day care has been suggested. This theory 
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has been linked to the age-dependent modifying influence of infections on the developing 
immune system (Atkinson and Eisenbarth, 2001).  
4.5.4.3 Specific immune response to cows' milk protein in type 1 diabetes 
The enhanced cellular and humoral immune responses to dietary antigens observed in type 1 
diabetes have not been directly implicated in the pathogenetic process. Alternatively, it could 
be explained by an impaired tolerance to dietary antigens due to regulatory defects in the gut 
immune system in general (Brandtzaeg, 2002; Vaarala, 2002; Flohé et al., 2003). Given the 
strong association between the HLA class II genes and susceptibility to autoimmune disease, 
the complex between an autoantigenic peptide, an MHC (Major Histocompatibility Complex) 
molecule and a T cell receptor is an obvious focus of interest (Parry et al., 1998). Several 
studies have investigated antibody as well as T cell responses to distinct cow’s milk proteins 
in diabetics compared to controls to identify possible diabetogenic factors. The main 
suspected milk antigens are bovine serum albumin (BSA), bovine insulin, β-lactoglobulin and 
β-casein (Karjalainen et al., 1992; Drash et al., 1994; Vaarala et al., 1996; Vaarala et al., 
1998; Monetini et al., 2002, 2003; Luopajärvi et al., 2008). 
Some studies have reported enhanced humoral immune response to various cow’s milk 
proteins in infancy in a subgroup of children fed standard, non-hydrolysed infant formula who 
later progress to type 1 diabetes (Luopajarvi et al., 2008). Elliott and Martin (1984) reported 
that addition of skim milk powder to a protein-free diet produced diabetes in the spontaneous 
diabetes model bio breeding (BB) rats with an incidence of 52%. A semi-synthetic amino acid 
diet reduced the incidence to 15%. The effect seemed to be established during the early 
postnatal period (Daneman et al., 1987). However, in another study, diabetogenic food 
components resulted in diabetes as late as puberty in the BB rat or even later in the non-obese 
diabetic (NOD) mouse (Coleman et al., 1990). In addition, not only milk ingestion but also 
introduction of meat and soy protein increased autoimmune diabetes in those animal models 
(Scott, 1990; Elliott et al., 1988). Other authors have not confirmed the effect of cows' milk 
protein on diabetes frequency. Malkani et al. (1997) reported that neither the addition of BSA 
to a milk protein-free diet nor the introduction of total milk protein increased the frequency of 
diabetes in BB Worcester rats. Hydrolysed formula was reported to induce protective effect 
against type 1 diabetes in NOD mice (Hermitte et al., 1995; Karges et al., 1997a,b). Diabetes 
could be prevented or reduced in BB rats and in NOD mice by introducing hydrolysed casein 
(Scott et al., 1985; Elliott et al., 1988; Issa-Chergui et al., 1988; Scott, 1990; Scott et al., 
2000) compared to other types of diet. Infants given hydrolysed formula showed a decreased 
immunological response to cow’s milk proteins compared to infants given conventional baby 
formula (Akerblom et al., 2005). 
The ICA69 sequences were shown to cross-react with cows' milk BSA and more particularly 
with the [152–168] amino acid residue called ABBOS. Elevated serum concentrations of IgG 
anti-BSA antibodies were detected in diabetic subjects. The majority of these anti-BSA 
antibodies were specific to the ABBOS peptide and cross-reacted with ICA69 (Beppu et al., 
1987; Glerum et al., 1989; Martin et al., 1991; Karjalainen et al., 1992; Pietropaolo et al., 
1993; Saukkonen et al., 1994; Levy-Marchal et al., 1995). Significantly increased T cell 
proliferation responses to BSA and ABBOS were found in children with newly diagnosed 
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type 1 diabetes (Cheung et al., 1994; Miyazaki et al., 1995). Elevated levels of anti-BSA 
antibodies were detected in diabetic animals (NOD mice, BB rats) and immunization of NOD 
mice with BSA or ICA69 generated cross-reactive T cell responses to both Tep69 and 
ABBOS (Karges et al., 1997). However, the role of BSA in type 1 diabetes was questioned 
since several authors could not confirm specifically enhanced humoral or cellular responses to 
BSA or ABBOS in diabetic patients compared to controls (Atkinson et al., 1993; Dosch et al., 
1994; Luhder et al., 1994; Ivarsson et al., 1995; Krokowski et al., 1995; Vaarala et al., 1996; 
Füchtenbusch et al., 1997). In NOD mice fed experimental diets prior to conception, no 
difference was found in the offspring in diabetes incidence between a standard diet and a 
milk-free diet (Paxson et al., 1997). Ronningen et al. (1998) found no cross-reactivity 
between BSA and ICA69 in human and animal experiments. Atkinson et al. (1993) concluded 
that anti-BSA antibodies may reflect a general impairment of immunological tolerance. This 
was associated with a general predisposition to autoimmunity rather than specific β-cell 
autoimmunity.  
It was also hypothesised that exposure to bovine insulin which differs from human insulin 
only by three amino acids, may break the tolerance to insulin and might cause primary 
immunisation to insulin in young infants (Vaarala et al., 1998; Paronen et al., 2000; Virtanen 
et al., 2000; Vaarala 2005; Marttila et al., 2008). Several animal experiments revealed a 
protective effect of orally administrated human insulin on diabetes type 1 incidence (Atkinson 
et al., 1990; Zhang et al., 1991; Bergerot et al., 1994; Ploix et al., 1998). After feeding human 
insulin to 6-week-old NOD mice for one month, Ploix et al. (1998) demonstrated a reduction 
in the severity of insulitis and diabetes incidence. This was due to the development of 
regulatory T cells suppressing the activity of autoreactive T cell clones. However, in children 
with HLA-conferred susceptibility to diabetes, administration of nasal human insulin, started 
soon after detection of autoantibodies, appeared not to prevent or even delay type 1 diabetes 
(Nantö-Salonen et al., 2008). It has been suggested that addition of human insulin to infant 
formula in a concentration similar to that present in human milk may be beneficial (Shehadeh 
et al., 2001). It is speculated whether this addition might protect from the development of 
type-1 diabetes and lead to even faster gut maturation (Shehadeh et al., 2001).  
The possibility that molecular mimicry occurs between casein and islet antigens (p69, 
carboxypeptidase, GLUT-2) has also been proposed. Cell-mediated immune responses to β-
casein were observed in patients with diabetes of recent onset compared to healthy controls. It 
was postulated that a sequence homology between residues 63–67 of bovine β-casein and 
415–419 of the β-cell-specific glucose transporter GLUT-2 could be the pathogenic 
mechanism (Inman et al., 1993; Cavallo et al., 1996a,b). Elevated levels of antibodies to β-
casein were demonstrated in some patients with type 1 diabetes but not in others (Wasmuth et 
al., 1995; Elliott et al., 1996a; Monetini et al., 2002, 2003). Ellis et al. (1998) found cellular 
immune responses to β-casein in type 1 diabetes compared to autoantibody negative healthy 
control subjects. T cell immune response to β-casein was the same in the diabetic patients and 
their autoantibody negative relatives. The authors concluded that individuals genetically prone 
to autoimmunity may be deficient in developing tolerance to dietary antigens. The role of β-
casein as a causative factor in diabetes development remains unclear. Animal experiments 
have produced contrasting results concerning the diabetogenic potential of casein. Some 
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studies demonstrated a protective effect of whole casein as a substitute for skim milk (Scott et 
al., 1985; Issa-Chergui et al., 1988; Scott, 1990), whereas others reported that introduction of 
β-casein as the only source of protein before weaning leads to the development of diabetes in 
NOD mice (Elliott et al., 1988). 
Beta-lactoglobulin (β-lg) is the major whey protein in cow’s milk (Rudloff and Kunz, 1997) 
but is not expressed by the human mammary gland. It was demonstrated that this protein is 
involved in allergic reactions to cow’s milk (Sabikhi, 2007). Enhanced humoral and cellular 
immune response to β-lg was also demonstrated in some diabetic patients compared with 
control subjects (Dahlquist et al., 1992; Savilahti et al., 1993; Saukkonen et al., 1995; Vaarala 
et al., 1996; Vähäsalo et al., 1996). A recent study points out a possible cross-reaction 
between anti-β-lg and the human protein glycodelin (PP14), a T cell modulator, undermining 
T cell regulation of beta cells in infancy (Goldfarb, 2008). Cellular responsiveness to β-lg was 
not associated with HLA-DQB1 risk alleles, implying that immune response to the protein 
does not reflect the accumulation of these HLA alleles in the patients with type 1 diabetes.  
The link between milk proteins and type 1 diabetes remains unclear. When genetic risk 
determinants were included, antibodies to BSA, β-lg, whole cow’s milk and islet cell 
antibodies were not independently associated with the risk of type 1 diabetes in a multivariate, 
logistic regression analysis (Saukkonen et al., 1995; Vähäsalo et al., 1996; Saukkonen et al., 
1998; Redondo et al., 1999). 
4.5.4.4 β-casein variants, BCM7 and type 1 diabetes   
After in vitro digestion with intestinal enzymes, BCM7 has been shown to be released at a 
higher level from β-casein variants A1 and B than from the A2 variant (see Chapter 3.2). A 
hypothesis has been proposed that the opioid peptide BCM7 might contribute to the 
impairment of the development of gut-associated immune tolerance in IDDM genetically 
predisposed individuals. It might thus act as an adjuvant in the autoimmune reaction involved 
in the destruction of β-cells in prediabetic subjects (Elliott et al., 1997; Hartwig et al., 1997; 
Åkerblom and Knip 1998; Elliott et al. 1999). One study has shown that antibodies against 
casein variants occur both in normal controls and in patients with IDDM. However, patients 
with IDDM and their siblings showed increased amounts of anti-casein A1 antibodies in 
serum samples, whereas their parents and control persons showed increased amounts of anti-
casein A2 antibodies in serum samples (Padberg et al., 1999). Although BCMIR can be 
present in the intestinal lumen, the specific release of BCM7 from β-casein variants A1 and B 
has not been demonstrated in vivo in humans (Svedberg et al., 1985) (see chapter 3). The 
diabetogenicity of β-casein A1, A2 and B variants has been evaluated in animal studies and in 
ecological studies in humans.  
Two animal studies have investigated the differences in the diabetogenic effect between A1 
and A2 casein (Elliott et al., 1997; Beales et al., 2002). Both feeding studies combined casein 
with a soy preparation in NOD mice. The first study which was not published in a peer-
reviewed journal, found a higher incidence of diabetes after feeding NOD mice with A1 β-
casein compared to A2 β-casein  (Elliott et al., 1997). In contrast, the second study was 
published in an international, peer-reviewed journal and did not confirm these results (Beales 
et al., 2002). In this study, the authors showed that the combination of A2 with soy protein 
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(Prosobee (PS), soy based formula) resulted in a lower incidence of diabetes in the BB rat, 
whereas the combination of  A1 and A2 with Pregestimil (a hydrolysed milk formula) did not 
result in a difference. However, the authors concluded that A1 β-casein was more 
diabetogenic than A2 β-casein in PS-fed BB rats, and that although milk caseins are unlikely 
to be exclusive promoters of type 1 diabetes, they could enhance the induction of diabetes in 
some cases. It should be taken into account that soy proteins have been suggested to 
contribute to the development of diabetes, as well as Pregestimil. In the study of Beales et al. 
(2002), wheat was shown to be much more diabetogenic than other protein combinations. The 
studies performed to date do not allow a conclusion on a direct effect, if any, of β-casein A1 or 
A2 on the development of diabetes in animal models.  
The first group of human ecological studies tested the correlation between the estimated per 
capita consumption of β-casein A1 and A2 and the incidence of type 1 diabetes. A study on 
type 1 diabetes incidence in 0 to 14-year-old children from 10 countries or areas, including all 
the Nordic countries, compared the national cow's milk protein consumption along with milk 
protein polymorphism. They observed that total protein consumption did not correlate with 
diabetes incidence but consumption of β-casein A1 alone or in combination with β-casein B 
did correlate with IDDM incidence (Elliott et al., 1999). The calculated consumption of β-
casein A1 across 16 countries was reported to correlate strongly with the incidence of type 1 
diabetes in males under 15 years (McLachlan, 2001). A larger ecological study, including 19 
countries from all over the world, reported similar associations (Laugesen and Elliott, 2003). 
However, the difference in the incidence of type 1 diabetes can also be explained by other not 
reported confounding factors  as already outlined for CVD, since the authors used the same 
estimated β-casein variants intakes for their statistical analyses (in Chapter 4.5.3.3). 
Moreover, as discussed in Chapter 2.3, the relevance of data on β-casein allele distribution 
and the actual level of specific protein variants in milk and dairy products appear difficult to 
interpret. 
A further ecological study evaluated the correlation between β-casein A1 and B intake and 
type 1 diabetes incidence in the group of Nordic countries: Iceland, Denmark, Norway, 
Sweden and Finland (Thorsdottir and Reykdal, 1997; Birgisdottir et al., 2002, 2006). The 
Icelandic population has a genetic origin similar to that of the other Nordic countries, except 
Finland (Wijsman, 1984). No major differences in HLA allele distribution between Icelandic 
and Norwegian diabetic patients or control groups could be found (Backman et al., 1998), 
although the incidence of type 1 diabetes in Norway has been reported to be about twice as 
high as in Iceland (Joner and Sovik 1989; Helgason et al., 1992). No association was found 
between cow’s milk consumption in infancy and the development of type 1 diabetes in the 
Icelandic population (Thorsdottir et al., 2000) whereas many studies have suggested that early 
ingestion of cow’s milk products in infancy is associated with an increased risk for the 
development of type 1 diabetes (Borch-Johnsen et al., 1984; Mayer et al., 1988; Virtanen et 
al., 1991; Kostraba et al., 1992, 1993; Gerstein 1994; Patterson et al., 1994). The study of 
Birgisdottir et al. (2006), focusing on children, reported a lower average consumption of β-
casein A1 and B variants  among 2-year old children in Iceland (approximately 1.7 g/day) 
compared to the same age group in the Scandinavian countries (Denmark, Norway, Sweden, 
Finland) (approximately 2.7 g/day) where the incidence of type 1 diabetes is higher. The 
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study also reported a positive correlation between the estimated intake of β-casein A1 among 
2 year olds in the different Nordic countries and the incidence of type 1 diabetes. 
However, a comprehensive evaluation of possible confounders and uncertainties is needed in 
order to assess the strenght of the above correlations. Dietary intakes in infancy and childhood 
may be expected to have a large inter-individual and age-related variation. Given the general 
limitations of ecological studies, the possibility that the children with type 1 diabetes had a 
low intake of β-casein A1 when compared to other children in the same country, cannot be 
rejected. Therefore, the possibility that other confounding factors are responsible for the 
disease, cannot be rejected by an ecological study. In the first step Birgisdottir et al. (2006) 
restricted the observed population to more homogeneous sex and age groups, in particular 
children at 2 years of age, and male as well as female adolescents aged from 11 to 14 years. 
The obtained correlation was only significant (to α=5%) for the youngest children and β-
casein A1. Some methodological problems can be highlighted, however. While the best 
available comparable data were used (Birgisdottir et al., 2006), the incidence rates of type 1 
diabetes covered the period up to the middle of the 90’s. However the consumption data for 
the different countries were taken between 1980 and 1999, while information regarding the β-
casein A1 and B were from early and late 1990s. 
In addition, the exposure to β-casein A1 versus A2 of IDDM and non-IDDM subjects needs to 
be considered. The β-casein A1+B content in milk produced in Iceland and in other Nordic 
countries in the late 90s was estimated to be 38.4 % and 48.7%, respectively (Thorsdottir et 
al., 2000). As a consequence, it can be seen that the IDDM and non-IDDM groups were both 
exposed to significant levels of β-casein A1+B. As a consequence, it seems difficult from an 
immunological viewpoint to explain the difference in incidence of IDDM by such a small 
difference in the estimated exposure to β-casein A1+ B. 
In summary, no specific putative factor could be identified in the reviewed literature for 
which a cause-effect relationship with IDDM could be proven. 
CONCLUSIONS 
Conclusions on bioactive peptides and source proteins 
• Proteins, including those present in the diet, are a potential source of a wide range of 
biologically active peptides, including some with affinity for opioid receptors. 
• The release of BCM7 through enzymatic digestion of bovine β-casein is dictated by the 
primary amino acid sequence, which is dependent on the genetic variant of this protein. 
• The allele frequency distribution of β-casein is determined by bovine breed and 
population. 
• Changing selection targets in the last decades has resulted in changes in bovine breed 
composition in most European countries. While no detailed information is available, it is 
likely that these changes in breed composition have had an impact on milk composition, 
including different milk protein variant concentration and type. 
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• Taking into account the uncertainty in milk composition and the diverse geographical 
origin of dairy products and ingredients across Europe, insufficient information is 
currently available on the exposure of individual consumers to different β-casein variants. 
Conclusions on opioid peptides in food and their formation during digestion 
• The presence of BCMs or related peptides in unprocessed milk obtained from healthy 
cows has not been conclusively demonstrated.  
• There is a substantial body of evidence indicating that different proteolytic systems 
involved in fermented milk or cheese manufacture can potentially hydrolyze β-casein to 
BCM7 or other BCMs and further degrade these peptides to shorter-chain peptides and 
even amino acids.  
• Little or no information is currently available about the actual BCM levels which different 
proteolytic systems may generate in fermented or enzyme treated milk products. 
Furthermore, the stability of these peptides, once generated, is variable. 
• Technological conditions such as heat treatments applied in industrial dairy processing do 
not seem to influence the occurrence of BCMs in the final products or influence their 
formation during subsequent digestion. 
• The role of proteolytic systems in favoring the release of BCMs during SGID or in vivo 
digestion, eventually through the formation of BCM precursors, has not been clarified. 
However, there are indications that a successive action of several digestive enzymes is 
involved. 
• Evidence about the occurrence of BCMs in commercial infant formulas is currently 
inconclusive. However, the subsequent formation of certain BCMs in infant formulae after 
SGID (with multiple enzyme activities) has been demonstrated.  
• No current studies report quantitative values for BCMs formed during the in vivo 
digestion of dairy products. 
Conclusions on molecular interactions, general biological effects and fate of 
food-derived peptides 
• Animal data clearly support the idea that β-casomorphins, including BCM7, can act as 
opioid receptor agonists, probably acting via μ-type opioid receptors. 
• At a molecular level, in comparison to medicinal and endogenous opioids, bovine BCM7 
does not seem to be a very potent opioid ligand.  
• Opioid effects were only observed in vivo in animal studies following intra-peritoneal 
(i.p.) or intra-cerebro-ventricular (i.c.v.) administration.  
• Relatively little is known on the mechanisms of transfer of intact peptides longer than 3 
amino acids across the intestinal barrier; however, if this transport occurs, then the extent 
is very low and passive diffusion is the most likely transfer mechanism. 
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• β-casomorphin immunoreactive material in blood has been reported in two studies within 
neonatal dogs and calves. However, the presence of β-casomorphin molecules in blood 
after intake of milk or casein has not been established in in vivo  studies.  
• Opioid peptides, including β-casomorphin 4, -5 and -7 are highly sensitive to hydrolysis 
by dipeptidyl peptidase IV thereby strongly limiting or preventing the transfer of these 
peptides in an intact form across the intestinal mucosa and the blood-brain barrier. 
• Available data suggest that in principle, transport of food-derived peptides and proteins 
across the human intestinal mucosa is possible. However, quantitative data on this 
phenomenon are lacking. In certain cases such as in neonates and adults with specific 
diseases, intestinal permeability has been reported to be significantly increased. 
Conclusions on organ and system specific actions 
• Food-derived peptides, including casomorphins, can have different effects in the intestinal 
lumen and the intestinal mucosa, such as regulatory effects on gastro-intestinal motility 
and on gastric and pancreatic secretions. 
• Many studies report effects of β-casomorphins on the CNS following i.p. or i.c.v. 
administration in animals. 
• A possible link between BCM intake and sudden infant death syndrome (SIDS) has been 
suggested in some publications. However, no clear evidence for such a relationship was 
found during the review. 
• A link between casein-derived peptides and autism in subjects with increased intestinal 
permeability has been suggested. However, recent data do not provide any support for 
such a relationship. 
• It has been suggested that BCM7 might be atherogenic through an oxidative action on 
LDL. This mechanism was originally proposed in a single report, however, it has not been 
confirmed by later studies. 
• The possibility that BCM7 could contribute to an increased risk for atherosclerosis has 
also been suggested from a study in a rabbit model. This study concluded that β-casein A1 
would be atherogenic, in contrast to β-casein A2. However, the validity of the 
experimental model and the extrapolation to atherosclerosis in human were not regarded 
as convincing. 
• Some ecological studies have linked the intake of BCM7 with cardiovascular disease 
mortality. However, these ecological studies did not account for several confounding 
factors. In addition, recent large cohort studies led to opposite conclusions. 
• Two human intervention studies comparing diets containing β-casein A1 and A2 did not 
show a correlation between the estimated β-casein A1 consumption and development of 
certain biomarkers for cardiovascular disease. A limitation of these studies was the small 
number of subjects and the short intervention period. 
• Overall, this review process did not find any strong evidence for a link between the 
consumption of β-casein A1 and an increased risk for CVD in humans. 
 Review of the potential health impact of β-casomorphins and related peptides 
 
 
EFSA Scientific Report (2009) 231, 62-107 
 
• Insulin dependent diabetes mellitus (IDDM) is recognised as a multifactorial autoimmune 
disease; however, its pathogenesis is unclear. 
• Autoantibodies have been found in IDDM patients, but the role of autoantibodies in type 1 
diabetes is currently not known. These autoantibodies have not been proven to be directly 
involved in either tissue destruction or disease progression. 
• The development of IDDM is the result of a combination of genetic predisposition and 
environmental risk factors where genetic predisposition is a necessary condition. 
• Many dietary risk factors of IDDM have been indicated, including short duration of breast 
feeding, gluten, soy, cow’s milk and solid foods at young age. 
• Several different milk proteins or peptides derived from these proteins have been 
proposed as possible diabetogenic factors. The mechanism most often suggested is 
immunological. 
• The diabetogenicity of β-casein A1, A2 and B has been evaluated in animal studies and 
ecological studies on humans. Animal studies have presented contradictory results. 
• Some ecological studies have linked the intake of BCM7 with IDDM. Ecological studies 
have the shortcoming of being unable to establish cause-effect relationship and they 
cannot adjust for possible confounding factors. They are at best indicating a hypothesis 
but cannot provide a proper base to demonstrate a cause-effect relationship. 
• The correlations suggested by these studies may become very weak when taking into 
account the uncertainties in individual consumption, in the β-casein variant composition, 
and in some countries also the IDDM incidence rate. 
• The difference in content of β-casein A1+B in milk produced in countries with high or low 
prevalence of IDDM appears relatively small and does not explain, from an  
immunological point of view, the difference in incidence of IDDM across countries. 
RECOMMENDATIONS 
Based on the present review of available scientific literature, a cause-effect relationship 
between the oral intake of BCM7 or related peptides and aetiology or course of any suggested 
non-communicable diseases cannot be established. Consequently, a formal EFSA risk 
assessment of food-derived peptides is not recommended. 
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GLOSSARY/ ABBREVIATIONS 
BCM7 (BCMn) β-casomorphin-7 (β-casomorphin-n) 
BCMIR β-casomorphin immunoreactive material 
BCMs β-casomorphins 
BSA Bovine serum albumin 
CEP Cell envelope proteinases 
CN Casein 
ConA Concavalin A 
CVD Cardiovascular disease 
ESI Electro spray ionisation 
GI Gastrointestinal  
HDL High density lipoprotein 
HLA Human leukocyte antigen  
HPLC High performance liquid chromatography 
i.c.v. Intra-cerebro-ventricular injection 
i.p. Intra-peritoneal injection 
ICA Islet Cell Autoantigen 
IDDM Insulin-dependent diabetes mellitus  
IUPHAR International Union of Basic and Clinical Pharmacology 
LAB Lactic acid bacteria 
LAP Leucine amino peptidase 
LC Liquid chromatography 
LDL Low density lipoprotein 
LPS Lipopolysaccharide 
MALDI Matrix assisted laser desorption ionisation 
MS Mass spectrometry (also as detection/identification tool connected with LC) 
PepX X-prolyldipeptidyl aminopeptidase 
PHA  Phytohemagglutinin 
SCC Somatic cell count 
SGID Simulated gastro intestinal digestion 
TOF Time of flight 
UF Ultra filtration 
UHT Ultra high temperature / short time heat treatment 
UV Ultra violet 
 
